Lancet by Allemani, Claudia et al.
Global surveillance of trends in cancer survival: analysis of 
individual records for 37,513,025 patients diagnosed with one of 
18 cancers during 2000–2014 from 322 population-based 
registries in 71 countries (CONCORD-3)
Claudia Allemani1, Tomohiro Matsuda2, Veronica Di Carlo1, Rhea Harewood1, Melissa 
Matz1, Maja Nikšić1, Audrey Bonaventure1, Mikhail Valkov3, Christopher J Johnson4, 
Jacques Estève5, Olufemi J Ogunbiyi6, Gulnar Azevedo e Silva7, Wan-Qing Chen8, Sultan 
Eser9, Gerda Engholm10, Charles Stiller11, Alain Monnereau12, Ryan Woods13, Otto 
Visser14, Gek Hsiang Lim15, Joanne Aitken16, Hannah K Weir17, Michel P Coleman1, and 
CONCORD Working Group
1Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London 
School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK 2Population-
based Cancer Registry Section, Division of Surveillance, Center for Cancer Control and 
Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan 
3Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, 
Arkhangelsk, Russian Federation 4Cancer Data Registry of Idaho, 615 North 7th Street, Boise ID 
83701-1278, USA 5Université Claude Bernard,162 Avenue Lacassagne, F-69003 Lyon, France 
6Ibadan Cancer Registry, University City College Hospital, PMB 5116 Ibadan, Dyo State, Nigeria 
7Department of Epidemiology, Universidade do Estado do Rio de Janeiro, 524 rua São Francisco 
Xavier, Maracanã, Rio de Janeiro RJ, Brazil 8National Office for Cancer Prevention and Control 
and National Central Cancer Registry, National Cancer Center, No.17 Pan-jia-yuan South Lane, 
Chaoyang District, 100021 Beijing, China 9Hacettepe University Institute of Public Health, 06100 
Sıhhiye, Ankara, Turkey 10Danish Cancer Society, Documentation and Quality, Strandboulevarden 
49, DK-2100 Copenhagen Ø, Denmark 11National Cancer Registration and Analysis Service, 
Public Health England, London SE1 8UG, UK 12Registre des hémopathies malignes de la 
This manuscript version is made available under the CC BY-NC-ND 4.0 license.
Corresponding author: Dr Claudia Allemani PhD, claudia.allemani@lshtm.ac.uk. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Contributors
CA, AB, CS and MPC drafted the protocol; CA and MPC obtained statutory and ethical approvals; GAS, WQC, GE, SE, CJJ, GHL, 
AM, TM, OJO, MV and HKW contributed to data acquisition; CA, VDC and MPC prepared the life tables; CA, VDC, RH, MM, MN, 
AB and MPC had access to all the raw data; CA, VDC, RH, MM, MN, AB, CJJ and MPC did the data preparation, quality control and 
analyses, and CA, VDC, RH, MM, MN, AB, JA, GE, JE, SE, OV, RW and MPC checked the results; CA and MPC drafted the report. 
All authors contributed to writing the final report and approved the version to be published. All members of the CONCORD Working 
Group had access to the results of all steps of data preparation, quality control and analyses, and contributed to interpretation of the 
findings.
Conflicts of interest
We declare no conflicts of interest.
HHS Public Access
Author manuscript
Lancet. Author manuscript; available in PMC 2019 March 17.
Published in final edited form as:
Lancet. 2018 March 17; 391(10125): 1023–1075. doi:10.1016/S0140-6736(17)33326-3.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gironde, Institut Bergonié, F-33076 Bordeaux, France; French Network of Cancer Registries 
(FRANCIM), Toulouse, France 13British Columbia Cancer Registry, BC Cancer Agency, 675 W 
10th Avenue, Vancouver BC, Canada V5Z 1L3 14Netherlands Cancer Registry IKNL, POBox 
19079 Utrecht 3501 DB, The Netherlands 15National Registry of Diseases Office, Health 
Promotion Board, 3 Second Hospital Avenue, Singapore 168937 16Cancer Council Queensland, 
553 Gregory Terrace, Fortitude Valley, Queensland 4006, Australia 17Division of Cancer 
Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, 
MS-F76 Atlanta GA 30341-3742, USA
Abstract
Background—In 2015, the second cycle of the CONCORD programme established global 
surveillance of cancer survival, as a metric of the effectiveness of health systems and to inform 
global policy on cancer control.
Methods—CONCORD-3 updates the world-wide surveillance of cancer survival to 2014, with 
individual data for 37.5 million patients diagnosed with cancer during the 15-year period 2000–
2014. Data were provided by 322 population-based cancer registries in 71 countries and territories, 
of which 47 provided data with 100% population coverage. The study includes 18 cancers or 
groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), 
cervix, ovary, prostate and melanoma of the skin in adults, and brain tumours, leukaemias and 
lymphomas in both adults and children. Standardised quality control procedures were applied; 
errors were rectified by the registry concerned. We estimated five-year net survival. Estimates 
were age-standardised with the International Cancer Survival Standard weights.
Findings—For most cancers, five-year net survival remains among the highest in the world in the 
US and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway and Sweden. For 
many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends 
are generally increasing, even for some of the more lethal cancers: in some countries, survival has 
increased by up to 5% for cancers of the liver, pancreas and lung. For women diagnosed during 
2010–2014, the predicted five-year survival for breast cancer is now close to 90% in the US and in 
Australia, but international differences remain very wide, with levels as low as 40% in South 
Africa.
For gastrointestinal cancers, the highest levels of five-year survival are seen in South-East Asia, in 
Korea for cancers of the stomach (69%), colon (72%) and rectum (71%), in Japan for oesophageal 
cancer (36%) and in Taiwan for liver cancer (28%). By contrast, in the same world region, survival 
is generally lower than elsewhere for melanoma of the skin (60% in Korea, 52% in Taiwan, 50% 
in China), and for both lymphoid malignancies (53% in Korea, 51% in Taiwan, 38% in China) and 
myeloid malignancies (46% in Korea, 33% in Taiwan, 25% in China). For children diagnosed 
during 2010–2014, five-year survival for acute lymphoblastic leukaemia ranged from 66% in 
Thailand to 95% in Finland. Five-year survival from brain tumours in children is higher than for 
adults, and the global range is very wide (from 45% in Thailand to 80% in Sweden and Denmark).
Interpretation—The CONCORD programme enables timely comparisons of the overall 
effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of 
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all cancers diagnosed world-wide every year. It contributes to the evidence base for global policy 
on cancer control. From 2017, the Organisation for Economic Co-operation and Development will 
use findings from the CONCORD programme as the official benchmark of cancer survival, among 
their indicators of the quality of health care in 48 countries world-wide. It is crucial for 
governments to recognise population-based cancer registries as key policy tools that can be used to 
evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for 
all patients diagnosed with cancer.
Keywords
population-based cancer registry; net survival; surveillance; global health
Introduction
The incidence of cancer continues to rise, both in high-income countries and, especially, in 
low- and middle-income countries. Prevention is crucial, but implementation has been slow 
and incomplete, even in high-income countries. Prevention is a long-term strategy, and not 
all cancers can be prevented.1 To reduce cancer mortality, it is necessary both to reduce 
cancer incidence and to improve cancer survival.
Many cancer patients will continue to be diagnosed every year for decades to come: an 
estimated 14 million patients a year world-wide around 2012,2 with a 50% projected 
increase to 21.6 million patients a year by 2030.3 Those patients will all need prompt 
diagnosis and optimal treatment, to improve their survival. Monitoring the effectiveness of 
national and regional health systems in treating and caring for these patients becomes ever 
more crucial.
In 2016, the WHO Executive Board recommended strengthening health systems to ensure 
early diagnosis and accessible, affordable, high-quality care for all cancer patients.3 The 
World Health Assembly followed up with a resolution on cancer control in May 2017. It 
included recommendations that national cancer control strategies should aim to reduce late 
presentation, ensure appropriate treatment and care for potentially curable malignancies such 
as acute leukaemia in children, “to increase survival, reduce mortality and improve quality 
of life.”4
President Tabaré Vázquez of Uruguay and WHO Director-General Tedros Ghebreyesus 
recently called for all countries “to provide universal health coverage, thereby ensuring all 
people can access needed preventive and curative health-care services, without falling into 
poverty.”5 Their call relates to all non-communicable diseases, including cancer. Population-
based cancer survival is one metric that can help evaluate whether all people have access to 
effective treatment services.
In 2015, the CONCORD programme established global surveillance of cancer survival for 
the first time,6 with publication of trends in survival over the 15-year period 1995–2009 
among patients diagnosed with cancer in 67 countries that were home to two-thirds (4.8 
billion) of the world’s population. In 40 countries, the data had 100% national population 
coverage. CONCORD-2 incorporated centralised quality control and analysis of individual 
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data for 25,676,887 patients diagnosed with one of 10 common cancers that represented 
63% of the global cancer burden in 2009. The 279 population-based registries covered a 
combined total population of 896 million people.
The US National Cancer Institute, in an invited commentary7 for The Lancet, noted that the 
global analyses of cancer survival in CONCORD-2 provided insights from countries with 
successful cancer control initiatives that could be applied in other regions, and that the 
availability of better data “provides a clearer picture of the effect of cancer control 
programmes on the ultimate goal of improving survival and reducing the effect of cancer on 
the social and economic development of countries.”
The US Centers for Disease Control and Prevention (CDC) described CONCORD-2 as the 
start of global surveillance of cancer survival,a with survival estimates “that can be 
compared, so scientists can begin to determine why survival differs among countries. This 
could lead to improvements in cancer control programs.” The results from CONCORD-2 
influenced national cancer control strategy in the UK in July 2015.8,9 In September 2015, 
the International Atomic Energy Agency’s Programme for Action on Cancer Therapy 
(PACT) used the results to launch a world-wide campaignb to highlight the global divide in 
cancer survival, and to raise awareness of persistent inequalities in access to life-saving 
cancer services.10 Further analysis of survival trends and disparities by race and stage at 
diagnosis in 37 US states are included in a forthcoming supplement to Cancer,11,12 designed 
to improve cancer control in the US.
CONCORD-3 updates world-wide surveillance of cancer survival trends to include patients 
diagnosed up to 2014, with follow-up to 31 December 2014. In countries that were already 
involved, more registries are participating, and 8 more countries have joined the programme. 
Follow-up for patients diagnosed during 2000–2009 with one of the 10 cancers included in 
CONCORD-2 has been updated. CONCORD-3 includes data for patients diagnosed during 
2000–2014 with one of 18 malignancies that represent 75% of the global cancer burden 
(Table 1). In addition to information on stage at diagnosis, we have collected data on tumour 
grade and the first course of treatment. Findings are published within 3 years of the end of 
follow-up.
Methods
Cancer registries
We contacted 412 cancer registries in 85 countries: 20 in Africa (13 countries), 45 in Central 
and South America (15 countries), 68 in North America (2 countries), 80 in Asia (20 
countries), 189 in Europe (33 countries) and 10 in Oceania (2 countries).
When the data call for CONCORD-3 was issued in May 2016, 12 of the 279 cancer 
registries that had participated in CONCORD-2 were no longer operational. The registry in 
Benghazi (Libya) was disrupted by war, the registry in Macerata (Italy) ceased operating, the 
ahttps://www.cdc.gov/cancer/dcpc/research/articles/CONCORD-2.htm
bhttps://www.youtube.com/watch?v=cXJ79_hxdNA
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Department of Health ceased funding the UK National Registry of Childhood Tumours in 
2013, and the 9 English regional cancer registries were replaced by a single cancer registry 
for England in 2013. Of the 267 remaining registries, nine could no longer provide up-to-
date follow-up of all registered patients, while 13 did not reply to repeated approaches. Data 
from the Tirol (Austria) registry are no longer reported separately from the Austrian national 
estimates. In all, 244 (87%) of the 279 registries (63 of the 67 countries) that participated in 
CONCORD-2 submitted data.
Of the 133 registries that had not previously participated in the CONCORD programme, 108 
agreed to do so. Of these, 85 (78%) registries in 12 countries submitted data, while 11 were 
unable to complete follow-up of registered cancer patients for their vital status, 9 made no 
further contact, and 3 signed up too late.
Of the 329 registries that submitted data, 7 were excluded because their data were not 
compliant with the protocol and could not be rectified in time. These exclusions affected the 
only participating registry or registries from several countries: Tunisia (Central Region), 
Bosnia Herzegovina (Republika Srpska), Saudi Arabia and Serbia (Central Region and 
Vojvodina). We analysed data provided by 322 cancer registries (81% of the 400 operational 
registries invited) in 71 countries and territories (text-figure 1), for patients diagnosed with 
cancer during the 15-year period 2000–2014, with data on their vital status at least five years 
after diagnosis, or at 31 December 2014.
Eight countries are participating in the global surveillance of cancer survival for the first 
time: Africa: Morocco; Central and South America: Costa Rica (national), Mexico 
(children, national), and Peru; Asia: Iran, Kuwait (national) and Singapore (national), and 
Europe: Greece (children, national).
Protocol
The CONCORD-3 protocol defining the data structure, file transmission procedures and 
statistical analyses was expanded and updated from the CONCORD-2 protocol, with the 
addition of variables on five additional cancers or groups of malignancies, tumour grade, and 
the modality and date of the first course of treatment by surgery, radiotherapy or systemic 
therapy.
In a study of this scale, adherence to protocol is critical. The protocol and analytic 
approaches were discussed with CONCORD Working Group members from 27 countries at 
a one-day meeting in Marrakech, Morocco, in October 2016. The protocol was also 
discussed at workshops in China, the Russian Federation, Romania, Singapore and the USA 
(for North America), and in conference calls with Costa Rica, Hong Kong, Malaysia, 
Mauritius, Mexico and Mongolia.
English is still a barrier to communication in many countries, so the CONCORD-3 protocol 
was translated into eight other languages: Arabic, Chinese (Mandarin), French, Italian, 
Japanese, Portuguese, Russian and Spanish. Translations were done by native speakers in the 
CONCORD Central Analytic Team in London or the wider CONCORD Working Group, 
and checked against the English original by other native speakers. The protocol was made 
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available to participants in all nine languages on the CONCORD web-site. The Central 
Analytic Team communicates with participants in six languages.
We examined survival for 18 cancers or groups of malignancies (“index cancers”): 
oesophagus, stomach, colon, rectum, liver, pancreas, lung, melanoma of the skin, breast 
(women), cervix, ovary and prostate in adults (15–99 years); brain tumours, myeloid and 
lymphoid malignancies in adults, and brain tumours, acute lymphoblastic leukaemia (ALL) 
and lymphomas in children (0–14 years). Collectively, these cancers accounted for about 
75% of the estimated number of patients diagnosed with cancer world-wide each year 
around 2012 (10,537,411 of 14,067,894, excluding non-melanoma skin cancer; Table 1).13 
The overall proportion is very similar in Northern America, Europe, Australia, New Zealand 
and Japan (“developed countries”) and in other world regions (“developing countries”), but 
it varies widely between cancers: prostate cancer is proportionately three times more 
common in developed countries, and cervical cancer four times more common in developing 
countries.
Solid tumours were defined by anatomic site (topography), and the leukaemias, lymphomas 
and melanoma of the skin by morphology (Table 2). Topography and morphology were 
coded to the International Classification of Diseases for Oncology (third edition, ICD-O-3),
14
 including its first revision.15 We restricted estimation of survival for melanomas to those 
arising in the skin, including the skin of the labia majora, vulva, penis and scrotum (ICD-
O-3 C51.0, C51.9, C60.9, C63.2). Melanomas arising in internal organs were included with 
all other malignancies in those organs. For ovarian cancer, we included the fallopian tube, 
uterine ligaments and adnexa, as well as the peritoneum and retroperitoneum, where high-
grade serous ovarian carcinomas are often detected.16 Registries were not asked to select 
cancers by sex, although some did so. Where data sets did include records for breast cancer 
in men, the proportion was consistently around 0.7%; these records were excluded. We also 
excluded small numbers of retroperitoneal malignancies in men, as well as Kaposi sarcoma, 
and tumours in solid organs with haematopoietic morphology.
Registries provided data for all haematopoietic malignancies (ICD-O-3 morphology codes in 
the range 9590–9992) in adults and children, to minimise differences in the spectrum of 
leukaemias and lymphomas submitted for analysis. In consultation with specialists in the 
HAEMACARE17 and InterLymph18,19 groups, we agreed to analyse survival for adults in 
two broad groups: lymphoid malignancies (HAEMACARE groups 1–19) and myeloid 
malignancies (groups 20–25; Table 2, web-table 1).
For children, we agreed to present survival estimates separately for ALL and lymphomas, 
based on ICD-O-3 codes, grouped according to the third edition of the International 
Classification of Childhood Cancer (ICCC-3).20 The first revision of ICD-O-3, published in 
2013,15 introduced eight new entities for acute lymphoblastic leukaemia/lymphoma 
(morphology codes 9811–9818). These new entities were not used at all by registries in 42 
of the 58 countries that submitted data for children diagnosed with ALL during 2010–2014, 
and very rarely in eight countries (combined number of children coded to a new entity below 
100), but the proportions ranged from 11% to 89% in large data sets from Australia, 
Belgium, Canada, the Netherlands, Puerto Rico, Singapore, Taiwan and the US. The overall 
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proportion for all 58 countries combined during 2010–2014 was 29% (10,679 of 36,867 
children). We therefore included the new entities in all analyses. They were included among 
the acute lymphoblastic leukaemias if the anatomic site was coded as blood, bone marrow, 
reticulo-endothelial or haematopoietic systems (not otherwise specified) (C42.0–42.1, 
C42.3–42.4), or unknown primary site (C80.9). Otherwise such malignancies were included 
with the lymphomas (web-table 1).
Survival analyses include only primary, invasive malignancies (ICD-O-3 behaviour code 3), 
except for the brain, where benign tumours (behaviour code 0) are also included. To 
facilitate quality control and comparison of the intensity of early diagnostic and screening 
activity, registries were asked to provide data for all registered malignancies at each index 
site, including those that were benign, of uncertain or borderline malignancy (1), in situ (2), 
metastatic (6) or uncertain whether primary or metastatic (9).
Registries were asked to provide full dates (day, month, year) of birth, diagnosis and death 
or last known vital status, both for quality control and to enable comparable estimation of 
survival.21 Where the day or month of birth, or the day of the date of diagnosis, or the day or 
month of the date of last known vital status was missing, we used an algorithm (details on 
request) to standardise the imputation of missing dates for all populations.
Participating registries completed a questionnaire on their methods of operation, including 
data definitions, data collection procedures, coding of anatomic site, morphology and 
behaviour, the tracing of registered cancer patients to ascertain their vital status, and how 
tumour records are linked with data on vital status.
Patients diagnosed with two or more primary cancers at different index sites during 2000–
2014 were included in the analyses for each cancer, e.g. colon cancer in 2005 followed by a 
breast cancer in 2010. Survival was measured from the date of diagnosis until death, loss to 
follow-up or censoring. We retained the most complete record for patients with synchronous 
primary cancers in the same organ. If a patient was registered with two or more primary 
malignancies in the same index site during 2000–2014 (metachronous primaries), only the 
first was included in analyses.
North American registries define multiple primary cancers under the rules of the 
Surveillance Epidemiology and End Results (SEER) programme.22 Those rules accept more 
cancers as new primary cancers than the rules of the International Association of Cancer 
Registries (IACR),23 which are used by most cancer registries in other continents. The North 
American Association of Central Cancer Registries (NAACCR) kindly updated the program 
developed for CONCORD-2 to enable all North American registries to recode their entire 
incidence databases to the IACR multiple primary rules, before their data sets for 2000–2014 
were extracted for CONCORD-3.
Countries and territories were defined by their UN name, continent and code as of 2015.24 
The names of jurisdictions used in the text, tables, graphics, maps and web-appendix are 
those used for statistical purposes by the Statistics Division of the UN Secretariat; similarly, 
we use “national coverage” to contrast with “regional coverage” for statistical purposes. 
These designations and the presentation of data here do not imply any assumption regarding 
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the political affiliation of countries or territories, or the expression of any opinion 
whatsoever on the part of the CONCORD programme concerning the legal status of any 
country, territory, city or area or of its authorities, or concerning the delimitation of its 
frontiers or boundaries. Some names have been shortened for convenience (e.g. Korea for 
the Republic of Korea, Russia for Russian Federation): this does not carry any political 
significance.
Cyprus is a Member State of the European Union, but it is part of Asia. Costa Rica, Cuba, 
Guadeloupe, Martinique, Mexico and Puerto Rico (Caribbean and Central America) were 
grouped with South America as America (Central and South). World maps and 29 regional 
maps were prepared in ArcGIS® Release 10.3,25 using digital boundaries (shapefiles) from 
the Database of Global Administrative Areas (GADM 2.8).26
The population coverage of the data from participating registries is given as the proportion 
of the country or jurisdiction’s population, taken from the UN Population Division database 
for 2014,27 or from the authorities for Australia, Guadeloupe, Hong Kong, Poland, Portugal 
and Taiwan or the registries concerned. Belarus, Greece and Mexico provided data only for 
childhood cancers, so the populations used were for children (0–14 years), and Mali, 
Mongolia and Morocco only provided cancer data for women, so the female populations 
were used.
Quality control
As for the previous cycle of the CONCORD programme,6 we performed data quality checks 
in three phases: protocol adherence, exclusions, and editorial checks. After each phase, a 
detailed report was sent to each cancer registry for discussion, and correction of data where 
required.
First, registries were sent a report showing the percentage compliance with the protocol for 
each of 51 variables in each cancer file. Compliance less than 100% required correction 
and/or re-submission of data.
Next, we checked for logical inconsistencies between the variables in each tumour record. 
Exclusion criteria were defined a priori, based on experience from CONCORD-2, and 
extended to cover features of some of the five additional cancers such as Ann Arbor stage 
for the lymphomas, and 14 additional variables on tumour grade and treatment. The 
variables in each record were checked for logical coherence against 20 sets of criteria, 
including eligibility (e.g. age, tumour behaviour), definite errors (e.g. sex-site errors, invalid 
dates, impossible date sequence, missing vital status) and possible errors, including a wide 
range of inconsistencies between age, tumour site and morphology.6,28 Registries were sent 
‘exclusion reports’ for each index cancer and each calendar period, summarising the number 
of tumour records with each type of definite or possible error, the number registered from a 
death certificate only (DCO) or detected at autopsy, and the number and proportion of 
eligible patients whose data could be included in survival analyses. Registries were invited 
to request details of tumour records in which errors had been detected. Many registries used 
this information to update their databases. Where errors in classification, coding or 
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pathological assignment were identified, registries were asked to correct and re-submit their 
data.
Finally, we examined the proportion of tumour records with morphological verification of 
the diagnosis, whether from histology of a biopsy or surgical specimen, cytology of a smear 
or bone marrow aspirate, or from imaging or biomarkers, including tumours with a specific 
morphology code. We also examined the proportion of cases with non-specific morphology, 
the distributions of the day and month of the dates of birth, diagnosis and last known vital 
status, and the proportion of patients who died within 30 days, were lost to follow-up, or 
were censored within 5 years of diagnosis.
Follow-up for vital status
Cancer registries use various methods to determine the vital status (alive, dead, emigrated, 
lost to follow-up) of registered cancer patients.6 Among 243 registries that provided specific 
information on follow-up procedures, 242 (99%) determine the vital status of registered 
cancer patients using passive follow-up techniques, in which tumour registration records are 
regularly linked to a regional or national index of all death registrations, regardless of the 
cause of death. Linkages are usually based on a national identity or social security number 
that is stored in both records. Such linkages are increasingly done electronically, but manual 
scrutiny of printed lists is still required in places. Tumour records that match to a death 
record are updated with the date of death. Some registries routinely receive paper or 
electronic death certificates for their territory, but this is insufficient on its own, since death 
certificates that do not mention cancer are rarely included. Transcription errors can arise 
with identity numbers, so variables such as the name, sex and date of birth are often used to 
improve the probability of an accurate match between a cancer record and a death 
registration.
Many registries use electoral registers, hospital records or official databases, such as social 
insurance, health insurance and driving licences, to determine the date on which a patient 
was last known or believed to have been alive. Patients recorded as having migrated beyond 
the registry’s jurisdiction, or to another country, may be recorded as lost to follow-up, 
because the patient’s eventual death is unlikely to be recorded: they are censored from 
survival analysis on that date.
Active follow-up techniques are also used by 124 (51.0%) registries, which routinely contact 
the treating physician, GP or hospital administration to determine the vital status for each 
registered patient, often on a quarterly or annual basis. Some registries also determine the 
vital status by contact with the patient’s family, by telephone or home visit, or with the 
village administration.
Registries were asked to submit data with follow-up for at least 5 years or, for patients 
diagnosed during 2010–2014, until 31 December 2014. Registration and follow-up for 
patients diagnosed in 2000–2009 was updated, and new data sets were submitted.
Patients registered solely from a death certificate or diagnosed at autopsy were excluded 
from analyses, because their survival time is unknown.
Allemani et al. Page 9
Lancet. Author manuscript; available in PMC 2019 March 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Statistical methods
Most registries submitted data for patients diagnosed from 2000 to 2014, with follow-up to 
2014, although some registries only began operation after 2000, or provided data for less 
than 15 years. The study design for examining survival trends among patients diagnosed in 
three consecutive five-year periods was cohort, cohort, period. This design was also used for 
CONCORD-2,6 so it enables us to examine global trends in survival over a 20-year period, 
by including the estimates for patients diagnosed during 1995–1999.
The cohort approach is considered the gold standard,29,30 because it provides a survival 
estimate for a group of patients who were diagnosed during the same year or period, are 
likely to have been treated in similar fashion, and who have all been followed up for at least 
the duration of survival required, such as 5 years. This approach to the estimation of survival 
is easy to interpret, but other approaches are required when some patients have been 
followed up for less than 5 years.
We used the cohort approach for patients diagnosed in 2000–2004 and 2005–2009, because 
in most data sets, all patients had been followed up for at least five years. We used the period 
approach31 for patients diagnosed during 2010–2014, because five years of follow-up data 
were not available for all patients. This combination of cohort and period approaches 
facilitates monitoring of cancer survival trends over an extended time span, from the earliest 
to the most recent years of cancer registration for which follow-up data are available (web-
annex 1).32
To ensure comparability of survival trends from 1995,6 we estimated net survival up to five 
years after diagnosis for both adults and children. Net survival is the cumulative probability 
of surviving up to a given time since diagnosis (e.g. 5 years) after correcting for other causes 
of death (background mortality). We used the Pohar Perme estimator,33 which takes 
unbiased account of the higher competing risks of death in the elderly, implemented with the 
algorithm stns34 in Stata (version 14).35
To control for the wide differences in background mortality between participating 
jurisdictions and over time, we produced 8,790 life tables of all-cause mortality for each 
calendar year during 2000–2014 in the general population of each country or registry 
territory, by single year of age and sex, and by race/ethnicity in Australia (Northern 
Territory: Indigenous, non-Indigenous), Israel (Arab, Jewish), New Zealand (Māori, non-
Māori) and Singapore (Chinese, Malay, Indian).
For 120 registries, we obtained complete life tables that did not require interpolation or 
smoothing, for each calendar year 2000–2014.
For 207 registries, the method of life table construction depended on whether we received 
raw data (numbers of deaths and populations) or mortality rates, and on whether the raw data 
or the mortality rates were by single year of age (“complete”) or by five-year age group 
(“abridged”).
For 109 registries, we obtained death and population counts from the registry, or the relevant 
national statistical authority. We derived life tables for 2001 and 2013 if possible, each 
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centred on three calendar years of data (e.g. 2000–2002, 2012–2014) to increase the 
robustness of the rates. We constructed raw mortality rates from the death and population 
counts using a Poisson regression model with flexible functions,36 then smoothed and 
extended the rates to obtain complete life tables by sex and single year of age up to age 99 
years. Life tables for each calendar year 2002–2012 were created by linear interpolation 
between the 2001 and 2010 life tables.37 Rather than extrapolate, we used the life table 
centred on 2001 for 2000, and the life table centred on 2013 for 2014.
For 64 registries that provided abridged mortality rates, or complete mortality rates that were 
not smoothed, we used the Ewbank relational model38 with 3 or 4 parameters to interpolate 
(if abridged) and smooth the mortality rates for the registry territory against a high-quality 
smooth life table for a country with a similar pattern of mortality by age.39
Each set of life tables was checked with a standardised statistical summary on the earliest 
and latest year of available data, showing the data source and the method of construction and 
smoothing. For each sex and, where relevant, each race or ethnicity, the reports show the life 
expectancy at birth, the probability of death in the age bands 15–59, 60–84 and 85–99 years, 
and semi-log plots of the age-mortality rates, showing both the raw data points and the final 
smoothed life-table curve, and the model residuals by age group (web-annex 2).
Collection of authoritative raw data on the numbers of deaths and populations by age, sex 
and calendar year or period in participating jurisdictions proved more difficult than in 2013–
2014. For 34 registries, no reliable data on all-cause mortality could be obtained for the 
registry territory. We took national life tables published by the UN Population Division,27 
and interpolated and extended them to age 99 years with the Elandt-Johnson method.40
For the 42 participating states in the US, we used life tables by state, race and 
socioeconomic status, provided by the US National Cancer Institute (Mariotto A, NCI, 
personal communication, 26 January 2016).
For each country, registry and calendar period, we present age-standardised net survival 
estimates for each cancer at five years after diagnosis. For adults, we used the International 
Cancer Survival Standard (ICSS) weights,41 in which age at diagnosis is categorised into 5 
groups: 15–44, 45–54, 55–64, 65–74 and 75–99 years and, for prostate cancer, 15–54, 55–
64, 65–74, 75–84 and 85–99 years. Of the three sets of ICSS weights, we used group 2 
(cancers for which incidence does not increase steeply with age) for melanoma of the skin, 
cervix uteri and brain (adults), and group 1 (cancers for which incidence does increase 
steeply with age) for oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast, ovary 
and prostate, and both groups of haematopoietic malignancies. For children, we estimated 
survival for the age groups 0–4, 5–9 and 10–14 years; age-standardised estimates were 
obtained by assigning equal weights to the three age-specific estimates.41,42
Cumulative survival probabilities in the range 0–1 are presented for convenience as 
percentages in the range 0–100%. 95% confidence intervals for both unstandardised and 
age-standardised survival estimates were derived assuming a Normal distribution, truncated 
to the range 0–100. Standard errors to construct the confidence intervals were derived with 
the Greenwood method.43 If no death or censoring occurred within 5 years, or if all patients 
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died within five years (survival probability 1 or zero) we obtained a binomial approximation 
for the lower and upper bound, respectively, of the confidence interval.29
Survival was not estimated if fewer than 10 patients were available for analysis. If 10–49 
patients were available for analysis in a given calendar period, we only estimated survival 
for all ages combined. If 50 or more patients were available, we attempted survival 
estimation for each age group. If a single age-specific estimate could not be obtained, we 
merged the data for adjacent age groups and assigned the combined estimate to both age 
groups before standardisation for age. If two or more age-specific estimates could not be 
obtained, we present only the unstandardised estimate for all ages combined. We did not 
merge data between consecutive calendar periods.
The pooled estimates for countries with more than one registry do not include data from 
registries for which the estimates were less reliable. Less reliable estimates are reported with 
a flag when they are the only available information from a given country or territory.
Ethical approvals and confidentiality
We maintain approvals from the Ethics and Confidentiality Committee of the UK’s statutory 
Health Research Authority (HRA) (reference ECC 3–04(i)/2011, last update 3 March 2017) 
the National Health Service Research Ethics Service (11/LO/0331, 21 February 2017) and 
the London School of Hygiene and Tropical Medicine (12171, 6 September 2017). The 
HRA also approves the Cancer Survival Group’s System-Level Security Policy, governing 
data security. One investigator (MPC) maintains triennial certification with the Collaborative 
Institutional Training Initiative in Human Subjects Research for Biomedical Investigators 
(https://www.citiprogram.org, ID3327653, 2 May 2016). We maintain statutory and/or 
ethical approvals and data sharing agreements, usually with annual renewal, in 85 other 
jurisdictions participating in the CONCORD programme. Registries in all other jurisdictions 
obtain local approval. The data belong to the participating registries and are only used for 
purposes agreed in the CONCORD protocol.
Participants transmit data via a specially configured file transmission utility with 256-bit 
Advanced Encryption Security. The utility automatically generates a random, strong, one-
time password for each data file at the time of transmission, and emails it to a different 
address. Neither the password nor the address are seen by the sender. This avoids the need 
for confirmation of passwords by email or telephone. Tumour records are effectively 
anonymised: they do not contain the patient’s name, address, postcode, or any national 
identity or social security number. All variables are numeric or alphanumeric codes. Each 
registry is sent a set of unique codes that must be used in naming each cancer data file, 
including distinct filenames for any re-transmission. The codes have no meaning outside the 
study. Data files thus contain no information that could be used to identify a person or a 
cancer registry, and neither the name nor the content of the file indicates that it even contains 
cancer data. This enhances security, as well as facilitating efficient handling of thousands of 
data files.
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Role of the funding sources
The funding sources played no part in the design, data collection, quality control, analysis, 
interpretation of the findings, writing of the manuscript, or the decision to submit for 
publication. The corresponding author had full access to all data and responsibility for 
submission for publication.
Results
The CONCORD database 2000–2014
Data were analysed for 322 cancer registries in 71 countries in Africa (8 registries, 6 
countries), Central and South America (33 registries, 13 countries), North America (57 
registries, 2 countries), Asia (66 registries, 17 countries), Europe (149 registries, 31 
countries) and Oceania (9 registries, 2 countries) (Figure 1).
For 47 countries, data were provided with 100% coverage of the national population: 41 for 
both adults and children, and 6 for children only (Argentina, Belarus, France, Greece, 
Mexico and Switzerland) (Table 3). In the other countries, population coverage varied from 
less than 1% in India to 86% in the US. More than 80 cancer registries joined the 
CONCORD programme for the first time. The 322 participating registries cover a combined 
population of almost one billion people around 2014 (989,082,244; Table 4). Detailed maps 
of participating jurisdictions are shown in web-figures 1.1–1.30.
Coverage is now national in Australia, and contributions from additional registries increased 
the population coverage in another 14 of the 25 countries that participated in CONCORD-2 
with sub-national coverage: Africa: Algeria (from 1.6% to 6.0%); Central and South 
America: Brazil (5.7%, 7.7%), Chile (5.5%, 13.8%), Colombia (6.9%, 9.0%), Ecuador 
(33.8%, 40.2%); North America: the USA (83.2%, 85.8%); Asia: Japan (29.2%, 40.6%), 
Thailand (5.9%, 20.3%), Turkey (5.4%, 23.4%); Europe: France (18.4%, 21.7%), Italy 
(38.6%, 58.3%), Romania (3.1%, 5.0%), Russia (0.9%, 5.6%), Switzerland (47.4%, 54.7%); 
Oceania: Australia (90.8%, 100%). International coverage has been reduced by the loss of 
data from Indonesia (Jakarta) and from four countries in Africa: Gambia, Lesotho, Libya 
and Tunisia.
Three of the Polish registries that participated in CONCORD-2 now use a different or 
anglicised name, changing the alphabetical order in web-tables: Holy Cross (formerly 
Kielce), Lower Silesia (Wrocław) and Subcarpathia (Podkarpackie). All 16 voivodships of 
Poland are now included.
Four registries submitted data with wider territorial coverage than before. The Burgundy 
(Digestive) registry in France submitted data for both the Saône-et-Loire and the Côte-d’Or 
départements; the Biella registry (Italy) now covers the Provincia di Vercelli as well as 
Biella; the Milano (Italy) registry now covers Provincia di Milano and Lodi as well as the 
city of Milan, and the Cluj (Romania) registry expanded coverage from Cluj county to 
include Bistrița-Năsăud county.
We received more than 4,700 data sets.
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We examined individual cancer registrations for 42,218,671 patients diagnosed with an 
index cancer during the period 2000–2014 (Table 3). Of these, 2,701,998 (6.4%) were for an 
in situ cancer, mostly of the cervix (54.6% of 1,708,084 women), breast (10.6% of 
7,377,462 women), colon (4.4% of 4,619,536 adults) or prostate (0.6% of 6,069,630 men) 
(web-table 2). The proportions of in situ cancer are not directly comparable between 
countries, because some registries still do not record in situ malignancies, while others did 
not submit data for cancers where in situ malignancy is common. The variation between 
continents is still of interest: for cervical cancer, it ranged from 2.3% in African registries to 
24% in Central and South American registries, 37.4% in Asian registries and 82% in 
Oceania; US registries did not submit data for in situ cervical cancers, and only three 
Canadian provinces did so. The proportion of in situ breast cancers varied from 0.3% in 
African registries to 4–6% in Asia, Europe and Oceania and 17% in North America.
Patients with in situ cancer were not included in survival analyses. We excluded a further 
506,625 (1.7%) patients because the year of birth, the month or year of diagnosis, or the year 
of last vital status was unknown, or because the tumour was not a primary, invasive 
malignancy (behaviour code 3), or the morphology was that of Kaposi sarcoma or 
lymphoma in a solid organ, or for other reasons (Table 3). The proportion of records 
excluded for these reasons is shown for each cancer and each cancer registry in web-table 2.
Of the 38,771,959 patients otherwise eligible for inclusion in survival analyses, the records 
for 1,124,388 (2.9%) were excluded because the cancer was registered only from a death 
certificate or discovered at autopsy (Table 3), and 116,316 (0.3%) for other reasons. These 
included definite errors (unknown vital status, unknown sex, sex-site error, invalid date(s) or 
sequence of dates) and possible errors, such as apparent inconsistencies between age, cancer 
site and morphology (details on request). For example, we excluded hepatoblastomas in 
children older than 6 years, and multiple myeloma in persons aged less than 20 years, unless 
the record was confirmed as correct by the registry concerned.
Among the 37,507,799 patients available for survival analyses for all cancers combined 
(97% of those eligible for inclusion), pathological evidence of malignancy (histology, 
cytology or haematology) was available for 35,482,420 (94.6%) (Table 3). This proportion 
ranged from 88.6% in Asia, 90.1% in Africa and 92.4% in Central and South America, up to 
94–98% in Europe, Oceania and North America. Continental variation was much wider for 
some cancers (web-table 2).
Countries marked in the text with an asterisk are those for which survival estimates are 
based on data with national population coverage (100%). Survival estimates that are 
considered less reliable are flagged (§) in tables and graphics. These are data sets in which 
15% or more of patients were lost to follow-up or censored alive within five years of 
diagnosis. For patients diagnosed in 2010 or later, this criterion was applied for patients 
censored alive before 31 December 2014, the study closure date. Estimates are also flagged 
as less reliable if 15% or more of patients were registered only from a death certificate or at 
autopsy and excluded from analysis, since their survival is unknown. Finally, estimates are 
also flagged if 15% or more of patients were excluded from analysis because one or more 
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dates was incomplete: unknown year of birth, unknown month or year of diagnosis, or 
unknown year of last vital status.
In what follows, we present results in a similar structure for each group of cancers. Where 
possible, we also present graphics of national trends in cancer survival over the 20-year 
period 1995–2014. Estimates for patients diagnosed during 1995–99 are for countries that 
provided data for one of the 10 cancers included in CONCORD-2.6
Gastrointestinal cancers
Oesophagus—Results are available for 734,428 adults from 290 registries in 60 countries 
(Tables 2 and 4).
In 2010–2014, 5-year age-standardised net survival was in the range 10–30% in most 
countries, with a much wider range in Asia (web-figure 4). Most survival estimates were 
considered reliable (Table 5, web-table 4).
Survival was highest in Japan (36%), China (34%) and Korea* (31%), and below 30% in all 
other countries (Table 5, web-figure 2). Survival was in the range 20–30% in 11 countries: 
Mauritius*, Puerto Rico*, the US, 2 countries in western Asia (Israel*, Turkey), in 5 
European countries (North: Ireland*; West: Belgium*, Germany, the Netherlands*, 
Switzerland) and in Australia*.
Survival trends from 2000 to 2014 increased by 4–5% in Singapore*, 3 European countries 
(North: Denmark*, the UK*; West: Germany) and in the US (web-figure 3). Survival 
increased by 6–10% in China, Israel* and Japan, in 6 European countries (North: Ireland*, 
Norway*; South: Portugal*; West: Belgium*, the Netherlands*, Switzerland) and in 
Australia*. The increase in Korea* was 13%.
Stomach—Results are available for 2,019,382 adults from 294 registries in 62 countries 
(Tables 2 and 4).
Age-standardised five-year net survival was generally in the range 20–40%, with very wide 
variation in Asia (web-figure 4). Most estimates were considered reliable (Table 5, web-table 
4).
In 2010–2014, survival was very high in Korea* (69%) and Japan (60%), followed by 
Jordan* (56%) and Costa Rica* (46%) (Table 5, web-figure 2). Survival was in the range 
30–40% in 16 countries: in Canada and the US; in Puerto Rico* and Martinique*; 5 Asian 
countries (South: Malaysia (Penang), Singapore*; East: China, Taiwan*; West: Israel*); 6 
European countries (South: Italy, Portugal*; West: Austria*, Belgium*, Germany, 
Switzerland) and in Australia* (Table 5, web-figure 2).
Survival was in the range 20–29% in 25 countries (Mauritius*, Brazil, Kuwait*, Turkey, 20 
European countries, New Zealand*), and below 20% in Chile, Ecuador, Thailand and 
Bulgaria*.
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Survival trends between 1995–1999 and 2010–2014 were rather flat in most countries, but 
after 2000, survival increased by 5% in Canada and the US, Singapore* and in 6 European 
countries (North: Denmark*, Lithuania*, the UK*; East: Poland*; West: Austria*, the 
Netherlands*).
Over the same 20 years, 5-year survival increased by up to 10% in Israel*, Japan, Estonia* 
and Ireland*, and by 20% or more in China and Korea*.
Colon—Results are available for 4,198,637 adults from 296 registries in 65 countries 
(Tables 2 and 4).
Survival for colon cancer varied widely, especially in Central and South America, in Asia 
and in Europe (Figure 4A, web-figure 4). Most estimates were considered reliable (Table 5, 
web-table 4).
For patients diagnosed during 2010–2014, survival was higher than 70% in 4 countries: 
Israel*, Jordan*, Korea* and Australia*. Survival was in the range 50–69% in 26 countries: 
Mauritius*; in Costa Rica* and Puerto Rico*; in Canada and the US; in Japan, Singapore* 
and Taiwan*; in 17 European countries (North: Denmark*, Finland*, Iceland*, Ireland*, 
Norway*, Sweden*, the UK*; South: Italy, Portugal*, Slovenia*, Spain; West: Austria*, 
Belgium*, France, Germany, the Netherlands*, Switzerland) and in New Zealand* (Table 5, 
web-figure 2).
Survival ranged from 50% to 60% in 20 countries: in 4 Central and South American 
countries (Brazil, Martinique, Peru (Lima), Uruguay*); in 5 Asian countries (South: 
Malaysia (Penang) East: China, Hong Kong*; West: Kuwait*, Turkey) and in 9 European 
countries (North: Estonia*, Lithuania*, Latvia*; South: Croatia*, Malta*; East: Bulgaria*, 
Czech Republic*, Poland*, Slovakia*).
Five-year net survival was below 50% in Ecuador (48%), Thailand (47%), Russia (45%) and 
India (39%).
Survival trends between 1995–1999 and 2000–2014 were generally flat or increasing (web-
figure 3). Five-year survival increased over this period by 5–10% in 11 countries: in Canada; 
in Japan and Taiwan*, and in 7 European countries (North: Estonia*, Ireland*, Lithuania*, 
Norway*, Sweden*; South: Italy; West: the Netherlands*) and in Australia*.
Over the same period, survival increased by more than 10% in China, Israel* and Korea*, 
and in 8 European countries (North: Denmark*, Iceland*, Latvia*, the UK*; South: 
Slovenia*, Spain; East: Bulgaria*, Czech Republic*, Poland*).
Rectum—Results are available for 1,720,488 adults from 294 registries in 64 countries 
(Tables 2 and 4).
As for colon, five-year net survival for rectal cancer varied widely. The range of survival 
estimates in Asia for 2010–2014 was even wider than for colon cancer (web-figure 4). 
Almost all the survival estimates were considered reliable (Table 5, web-table 4).
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Survival was higher than 70% in Jordan* (73%), Korea* (71%), and Australia* (71%).
For patients diagnosed during 2010–2014, survival was in the range 60–69% in 24 countries: 
in Canada and the US; in 4 Asian countries (South: Singapore*; East: Japan, Taiwan*; West: 
Israel*), in 17 European countries: (North: Denmark*, Finland*, Iceland*, Ireland*, 
Norway*; Sweden*, the UK*; South: Italy, Portugal*, Slovenia*, Spain; West: Austria*; 
Belgium*; France, Germany, the Netherlands*, Switzerland); and in New Zealand* (Table 5, 
web-figure 2).
Survival was in the range 50–59% in 18 countries: in 7 countries in Central and South 
America (Argentina, Brazil, Costa Rica*, Martinique*, Peru (Lima), Puerto Rico*, 
Uruguay*); in 5 Asian countries (South: Malaysia (Penang); East: China, Hong Kong*; 
West: Kuwait*, Turkey) and in 6 European countries (North: Estonia*, Latvia*, Lithuania*; 
South: Malta*; East: Czech Republic*, Romania (Cluj)).
Five-year survival was below 50% in Slovakia* (49%), Poland* (48%), Croatia* (48%), 
Bulgaria* (46%), Ecuador (45%), Thailand (44%), Russia (42%) and India (30%).
Survival trends between 1995–1999 and 2000–2014 were generally increasing, especially 
since 2000, in Asia, Europe and Oceania (web-figure 3). Survival increased by 5–10% in 
Japan and Taiwan*; in Finland*, Italy and Sweden; and in New Zealand*.
Over the same period, 5-year survival increased by 10% or more in Canada; in China, 
Israel* and Korea*; in 13 European countries (North: Denmark*, Estonia*, Ireland*, 
Lithuania*, Norway*, the UK*; South: Portugal*, Spain, East: Bulgaria*, Czech Republic*, 
Poland*; West: the Netherlands*, Switzerland), and in Australia*. The increase was about 
20% in Korea* and Slovenia*.
Liver—Results are available for 1,178,364 adults from 291 registries in 61 countries (Tables 
2 and 4).
Five-year net survival was in the range 5–30% throughout 2000–2014 (web-figure 4). 
Estimates are often flagged as less reliable than for other solid tumours (Table 5, web-table 
4), because of the exclusion of higher proportions of DCO registrations (Table 3, web-table 
2).
For patients diagnosed during 2010–2014, age-standardised five-year net survival was 30% 
in Japan, and in the range 20–29% only in Korea*, Singapore* and Taiwan*; and in 
Belgium* and Italy.
Survival was in the range 10–19% in 32 countries: Canada and the US, in 4 countries in 
Central and South America (Argentina, Brazil, Martinique*, Puerto Rico*); in 4 Asian 
countries (East: China; West: Israel*, Kuwait*, Turkey); in 15 European countries (North: 
Iceland*, Ireland*, Latvia*, Norway*, Sweden*, the UK*; South: Portugal*, Spain; East: 
Poland*, Romania (Cluj); West: Austria*, France, Germany, the Netherlands*, Switzerland) 
and in Australia* and New Zealand*.
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Five-year survival was less than 10% in Denmark*, Slovenia*, Thailand, Czech Republic*, 
Russia and Estonia*.
In most countries, survival has changed very little during the 20-year period 1995–1999 to 
2000–2014. It increased by 5–10% in Canada and the US; in Japan; in 9 European countries 
(North: Denmark*, Ireland, the UK*; South: Italy, Spain; West: France, Germany, the 
Netherlands*, Switzerland) and Australia* and New Zealand*. Survival increased by more 
than 10% in China, Korea* and Taiwan*; and in Norway*, Portugal* and Sweden*.
Pancreas—Results are available for 1,229,379 adults from 290 registries in 59 countries 
(Tables 2 and 4).
Age-standardised five-year net survival estimates were generally in the range 5–15% 
throughout 2000–2014 (web-figure 4). As for liver cancer, some estimates are less reliable 
(Table 5, web-table 4), due to the high proportion of DCO registrations (Table 3, web-table 
2).
For patients diagnosed during 2010–2014, survival was higher in Kuwait* (24%) and 
Malaysia (Penang, 19%) (Table 5, web-figure 2). Survival was in the range 10–15% in 16 
countries: in Canada and the US; in Brazil and Martinique*; in China, Korea* and Turkey, in 
8 European countries (North: Estonia*, Ireland*, Latvia*, Norway*, Sweden*; South: 
Portugal*; West: Belgium*, Germany), and in Australia*. Five-year net survival ranged 
between 5% and 10% in 19 countries. Survival was very low in Russia (4%).
Trends in 5-year survival between 2000–2004 and 2010–2014 were generally flat, but 
increases of 3–5% were seen in Canada and the US; in Korea* and Singapore*, in 12 
European countries (North: Denmark*, Estonia*, Ireland*, Latvia*, Norway*, Sweden*, the 
UK*; South: Portugal*; East: Czech Republic*; West: Belgium*, the Netherlands*, 
Switzerland), and in Australia* (web-figure 3).
Lung
Results are available for 6,051,262 adults from 290 registries in 61 countries (Tables 2 and 
4).
Age-standardised five-year net survival was in the range 10–20% in most countries (Table 5, 
web-figure 4). Most estimates in Central and South America were less reliable, due to the 
high proportion of DCO registrations excluded from analysis (Table 5, web-table 4), 
although the proportion of DCOs has generally decreased world-wide (Table 3, web-table 3).
For patients diagnosed during 2010–2014, the five-year survival estimate was high in Japan 
(33%). It was in the range 20–30% in 12 countries: Mauritius*, Canada and the US; 4 Asian 
countries (East: China, Korea*, Taiwan*; West: Israel*), and 5 European countries (North: 
Latvia*, Iceland*, Sweden*; West: Austria*, Switzerland) (Table 5, web-figure 2). In most 
countries, however, survival was in the range 10–19%: in Martinique* and Puerto Rico*; in 
6 Asian countries (South: Malaysia (Penang), Singapore*; West: Cyprus*, Kuwait*, Qatar*, 
Turkey); in 21 European countries (North: Denmark*, Estonia*, Finland*, Lithuania*, 
Norway*; South: Croatia*, Italy, Malta*, Portugal*, Slovenia*, Spain; East: Czech 
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Republic*, Poland*, Russia, Slovakia*; West: Belgium*, France, Germany, Ireland*, the 
Netherlands*, the UK*); and in Oceania (Australia* and New Zealand*).
Survival was below 10% in Thailand, Brazil, Bulgaria and India.
Lung cancer survival trends between 1995–1999 and 2000–2014 were generally flat, but 
survival increased by 5–10% in 21 countries: in Canada and the US; in Israel*, Singapore* 
and Taiwan*; and in 15 European countries (North: Denmark*, Estonia*, Iceland*, Ireland*, 
Latvia*, Norway*, Sweden*, the UK*; South: Portugal*, Slovenia*; West: Austria*, France, 
Germany, the Netherlands*, Switzerland), and in Australia*. Survival increased by more 
than 10% in China, Japan and Korea* (Table 5, web-figure 3).
Melanoma of the skin
Results are available for 1,553,109 adults from 281 registries in 59 countries (Tables 2 and 
4).
Age-standardised 5-year net survival was in the range 60–90% in most countries (web-figure 
4). Most estimates were considered reliable (Table 5, web-table 4).
For patients diagnosed during 2010–2014, five-year survival estimates exceeded 90% in 14 
countries: in the US, and in 8 European countries (North: Denmark*, Sweden*, the UK*; 
West: Belgium*, France, Germany, the Netherlands, Switzerland); and in Australia* and 
New Zealand* (Table 5, web-figure 2).
Survival was in the range 80–89% in 14 countries: in Canada, in Israel* and in 12 European 
countries (North: Estonia*, Finland*, Iceland*, Ireland*, Norway*; South: Italy, Malta*, 
Portugal*, Slovenia*, Spain; East: Czech Republic*; West: Austria*).
Survival was in the range 70–79% in 10 countries: in 4 countries in Central and South 
America (Argentina, Brazil, Costa Rica*, Puerto Rico*); and in 6 European countries 
(North: Latvia*, Lithuania*; South: Croatia*; East; Poland*, Romania (Cluj), Slovakia*).
Survival was in the range 60–69% in 7 countries: in 5 Asian countries (South: India, 
Singapore*; East: Korea*, Japan; West: Turkey) and in Bulgaria* and Russia. Survival was 
below 60% in Ecuador and in 5 Asian countries (South: Thailand; East: China, Taiwan*; 
West: Jordan*, Kuwait*).
Trends between 2000–2004 and 2010–2014 were generally stable in North America, 
Oceania and Japan, and in several European countries, where five-year survival was already 
around 85–90% among patients diagnosed during 2000–2004. Survival increased by 5–10% 
in China and Korea*; 13 European countries (North: Denmark*, Estonia*, Latvia*, 
Lithuania*, UK*; South: Croatia*, Portugal*, Slovenia*; East: Bulgaria*, Czech Republic*, 
Poland*; West: Austria*, Belgium*).
Women’s cancers
Breast—Results are available for 6,422,553 women from 298 cancer registries in 66 
countries (Tables 2 and 4).
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The range of survival estimates is still wide in each continent, apart from North America and 
Oceania (Figure 4, web-figure 4). Most estimates were considered reliable (Table 5, web-
table 4).
For women diagnosed during 2010–2014, age-standardised five-year net survival was 85% 
or above in 25 countries: in Costa Rica* and Martinique*; Canada* and the US; in Israel*, 
Japan and Korea*; in 16 European countries (North: Denmark*, Finland*, Iceland*, 
Norway*, Sweden*, the UK*; West: Austria*, Belgium*, France, Germany, the 
Netherlands*, Switzerland; South: Italy, Malta*, Portugal*, Spain); and in Australia* and 
New Zealand* (Table 5, Figure 2B, web-figure 2).
Five-year survival was in the range 80–84% in 13 countries: 4 countries in Central and 
South America (Argentina, Brazil, Peru (Lima), Puerto Rico*); 5 Asian countries (South: 
Singapore*; East: China, Hong Kong*, Taiwan*; West: Turkey) and 4 European countries 
(North: Ireland*; East: Czech Republic*, Latvia*; South: Slovenia*). Survival was in the 
range 70–79% in 12 countries: in Cuba* and Ecuador; in Kuwait* and Mongolia*; and 8 
countries in Europe (North: Estonia*, Lithuania*; South: Croatia*; East: Bulgaria*, Poland*, 
Romania (Cluj), Russia, Slovakia*).
Survival was still low in Thailand (69%) and India (Karunagappally, 66%).
Five-year net survival continued to increase up to 2010–2014 in most countries in Central 
and South America, Eastern and Western Asia and in all of Europe. Even so, survival 
remains lower in Eastern Europe than in other parts of the continent. In North America and 
Oceania, five-year net survival approached 90% (Figure 3, web-figure 3).
Cervix—Results are available for 660,744 women from 295 cancer registries in 64 
countries (Tables 2 and 4).
The global range in cervical cancer survival is still wide (50–70%), especially in Central and 
South America, Asia and Europe (Table 5, web-figure 4). Most survival estimates are 
reliable (web-table 4).
For women diagnosed during 2010–2014, age-standardised five-year net survival was 70% 
or higher in 7 countries, of which 5 with national coverage: in Japan, Korea* and Taiwan*; 
in Denmark*, Norway* and Switzerland, and in Cuba* (Table 5, web-figure 2).
Survival was in the range 60–69% in 29 countries: Canada and the US; Brazil and Puerto 
Rico*; 5 countries in Asia (East: China, Hong Kong*; South: Singapore*; West: Israel*, 
Turkey), 18 countries in Europe, and in Australia* and New Zealand*.
Survival was in the range 50–59% in 5 countries in Central and South America (Argentina, 
Ecuador, Martinique, Peru (Lima), Uruguay*); in India, Kuwait* and Thailand, and in 6 
European countries (North: Latvia*, Lithuania*; East: Bulgaria*, Poland*, Russia; South: 
Malta*).
Over the 15 years up to 2014, five-year survival has increased by 4–6% in Japan and in 11 
European countries (North: Denmark*, Estonia*, Ireland*, Lithuania*, Norway*; the UK*; 
Allemani et al. Page 20
Lancet. Author manuscript; available in PMC 2019 March 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
South: Portugal*; East: Bulgaria*, Poland*; West: Switzerland) (web-figure 3). Survival 
increased by 8–10% in Cuba* and India. In China, five-year survival increased from 53% for 
women diagnosed during 2000–2004 to 68% in 2010–2014.
Ovary—Results are available for 865,501 women from 289 registries in 61 countries 
(Tables 2 and 4).
Age-standardised five-year net survival was mostly in the range 30–50%, with even wider 
variation in Europe and Asia (web-figure 4). Most survival estimates were reliable (Table 5, 
web-table 4).
For women diagnosed during 2010–2014, five-year survival was still below 50% in most 
countries, except Costa Rica* (62%) (Table 5, web-figures 2–4). Survival was in the range 
40–49% in 25 countries: in Canada and the US, in 8 countries in Asia (South: Singapore*; 
East: China, Korea*, Japan, Taiwan*; West: Israel*, Turkey), in 14 European countries 
(North: Denmark*, Estonia*, Finland*, Iceland*, Latvia*, Norway*, Sweden*; South: 
Portugal*, Spain; West: Austria*, Belgium*, France, Germany, Switzerland), and in 
Australia*.
Survival was in the range 30–39% in 19 countries: 4 in Central and South America 
(Argentina, Brazil, Ecuador, Puerto Rico*); in Kuwait* and Thailand, in 12 European 
countries (North: Ireland*, Lithuania*, the UK* South: Croatia*, Italy, Slovenia*; East: 
Bulgaria*, Czech Republic*, Poland*, Russia, Slovakia*; West: the Netherlands*), and in 
New Zealand*.
Survival was below 30% in Malta* (28%) and India (16%).
Survival trends between 1995–1999 and 2010–2014 were rather flat in most countries. 
However, five-year survival rose by 5–10% in the US; in Israel*, Korea* and Taiwan*; in 11 
European countries (North: Denmark*, Iceland*, Ireland*, Norway*, Sweden*; South: 
Portugal*, Spain; East: Bulgaria*, Poland*; West: France, Switzerland), and in Australia*. 
Survival increased by more than 10% in Estonia* and Latvia*, and by 20% in Japan.
Prostate
Results are available for 5,864,878 men from 290 registries in 62 countries (Tables 2 and 4).
Age-standardised five-year net survival was in the range 70–100% in most countries (web-
figure 4). Most estimates were reliable (Table 5, web-table 4).
For men diagnosed during 2010–2014, five-year survival was approaching 100% in Puerto 
Rico*, Martinique* and the US. Survival was higher than 90% in a further 22 countries: in 
Brazil and Costa Rica*; in Canada; in Israel*, Japan and Korea*; in 14 European countries 
(North: Iceland*, Ireland*, Finland*, Latvia*, Lithuania*, Norway*, Sweden*; South: Italy, 
Portugal*, Spain; West: Austria*, Belgium*, France, Germany), and in Australia* and New 
Zealand*.
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Survival was in the range 80–89% in 18 countries: in Argentina, Ecuador and Uruguay*; in 
6 Asian countries (South: Malaysia (Penang), Singapore*; East: Taiwan*; West: Jordan*, 
Kuwait*, Turkey); and in 9 European countries (North: Denmark*, Estonia*, the UK*; 
South: Croatia*, Malta*, Slovenia*; East: Czech Republic*; West: the Netherlands*, 
Switzerland).
Survival was approaching 80% in Russia (79%), Poland* (78%) and Romania (Cluj, 77%). 
It was 75% in Slovakia*, and below 70% in China (69%), Mauritius* (69%), Bulgaria* 
(68%) and Thailand (68%). Five-year survival was 44% in India.
Over the 20-year period between 1995–1999 and 2010–2014, age-standardised five-year net 
survival was rising in most countries. Survival increased by 5–10% in Brazil and Ecuador; in 
Canada; in China and Turkey; in Austria* and Portugal*; and in New Zealand*.
Five-year survival rose by more than 10% in Israel*, Taiwan* and Thailand, and in 12 
European countries (North: Finland*, Iceland*, Norway*, Sweden*; South: Croatia*, Italy, 
Malta*, Spain; West: France, Germany, the Netherlands*, Switzerland), and in Australia.
Survival increased by more than 20% in 13 countries: in Japan, Korea* and Malaysia 
(Penang), and in 10 European countries (North: Denmark*, Estonia*, Ireland*, Latvia*, 
Lithuania*, the UK*; South: Slovenia*; East: Bulgaria*, Czech Republic*, Poland*).
Brain—Results are available for 656,659 adults from 286 registries in 59 countries (Tables 
2 and 4).
Age-standardised five-year net survival was in the range 20–40% in most countries (web-
figure 4). Most estimates were considered reliable (Table 5, web-table 5).
For patients diagnosed during 2010–2014, five-year survival was higher than 40% only in 
Japan (46%) and Croatia* (42%).
Survival was in the range 30–40% in 22 countries: Canada, the US, Puerto Rico* and 
Martinique; in 8 Asian countries (South: Singapore*, East: China, India, Korea*; West: 
Israel*, Jordan*, Kuwait*, Turkey), in 9 European countries (North: Denmark*, Estonia*, 
Finland*, Ireland*, Norway*, Sweden*; West: Belgium*, Germany, Switzerland), and in 
Australia*.
Survival was in the range 20–29% in 20 countries: Chile and Ecuador; in Malaysia (Penang) 
and Taiwan*; in 15 European countries (North: Iceland*, Latvia*, the UK*; South: Italy, 
Malta*, Portugal*, Slovenia*, Spain; East: Czech Republic*, Poland*, Russia, Slovakia*; 
West: Austria*, France, The Netherlands*), and in New Zealand*. Five-year survival was 
15% in Thailand.
Trends in 5-year survival between 2000–2004 and 2010–2014 were generally rather flat, but 
survival increased by 3–5% in 15 countries: Martinique* and Puerto Rico*; in Canada; in 
Israel* and Thailand; in 9 European countries (North: Iceland*, Latvia*, Lithuania*, 
Norway*, Sweden*; South: Croatia*, Italy; West: France, Switzerland), and in New 
Zealand*.
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Survival increased by 6–10% in a further 13 countries: the US; in China, India 
(Karunagappally); Korea* and Singapore*, and in 7 European countries (North: Denmark*, 
Estonia*, Ireland*, the UK*; South: Malta*, Spain; West: the Netherlands*), and Australia*. 
A striking increase (18%) was observed in Japan.
Haematological malignancies
Myeloid malignancies—Results are available for 1,151,226 adults from 286 registries in 
61 countries (Tables 2 and 4).
Age-standardised five-year net survival was in the range 30–50% in most countries, although 
lower in Asia (web-figure 4). Most estimates were considered reliable (Table 5, web-table 
5).
For patients diagnosed during 2010–2014, survival was 55–60% in Belgium*, France, 
Germany and Sweden*; in the range 50–54% in Canada, Turkey and in 8 European 
countries (North: Ireland*, Lithuania*, Norway*; South: Portugal*, Spain; East: Romania 
(Cluj); West: the Netherlands*, Switzerland) and in Australia*.
Five-year survival was in the range 40–49% in 11 countries: the US, Martinique and Puerto 
Rico*, in Israel*, Korea* and Singapore*; in 4 European countries (North: Denmark*, 
Iceland*, the UK*; South: Italy), and in New Zealand*.
Survival was in the range 30–39% in 13 countries: Argentina, Brazil and Costa Rica*, in 
Japan, Malaysia (Penang) and Taiwan*; and in 7 European countries (North: Estonia*; 
South: Croatia*, Slovenia*; East: Czech Republic*, Russia, Slovakia*; West: Austria*). 
Survival was below 30% in Chile and Ecuador; in China, Kuwait* and Thailand; and in 
Latvia* and Poland*.
Over the 15 years between 2000–2004 and 2010–2014, age-standardised five-year net 
survival increased by 5–10% in 14 countries: in the US; in China, Japan, Singapore* and 
Taiwan*; in 8 European countries (North: Ireland*, the UK*; South: Portugal*, Spain; East: 
Poland*; West: Austria*, Belgium*, Germany) and in Australia*. Survival rose by more than 
10% in Korea*; and in Denmark*, the Netherlands* and Norway*.
Survival increased dramatically in both Lithuania* and Sweden* (27%) and the Czech 
Republic* (17%).
Lymphoid malignancies—Results are available for 3,011,054 adults from 289 registries 
in 62 countries (Tables 2 and 4).
Five-year age-standardised net survival was usually in the range 40–70% in most countries, 
lower in Asia and in Central and South America (web-figure 4). Most estimates were 
considered reliable (Table 5, web-table 5).
For patients diagnosed during 2010–2014, 5-year survival was 70% or higher in 6 European 
countries (North: Denmark*, Iceland*, Latvia*; West: Belgium*, France, Switzerland) and 
Australia*. Survival was in the range 60–69% in Mauritius*; Puerto Rico*, Canada and the 
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US; in Israel* and Kuwait*; and in 12 European countries (North: Finland*, Ireland*, 
Norway*, Sweden*, the UK*; South: Italy, Malta*, Portugal*, Spain; West: Austria*, 
Germany, the Netherlands*), and in New Zealand*.
Survival was 50–59% in 15 countries: in Costa Rica* and in 6 Asian countries (South: 
Malaysia (Penang), Singapore*; East: Japan, Korea*, Taiwan*; West: Turkey) and in 7 
European countries (North: Estonia*, Lithuania*; South: Croatia*, Slovenia*; East: Czech 
Republic*, Poland*, Slovakia*).
Survival was lower than 50% in 5 countries in Central and South America (Argentina, 
Brazil, Chile, Ecuador, Martinique); in China, India and Thailand; and in Bulgaria*, 
Romania (Cluj) and Russia.
Five-year survival trends between 2000–2004 and 2010–2014 were increasing in most 
countries. Survival increased by 5–10% in 22 countries: Ecuador; in Canada and the US; in 
Japan, Taiwan* and Thailand, in 15 European countries (North: Finland*, Estonia*, 
Iceland*, Sweden*; South: Croatia*, Portugal*, Slovenia*; East: Bulgaria*, Czech 
Republic*, Russia, Slovakia*; West: Austria*, Belgium*, France, Germany) and in New 
Zealand*.
Survival increased by more than 10% in 15 countries: in Puerto Rico*; in Korea*, Kuwait* 
and Singapore*; in 10 European countries (North: Denmark*, Ireland*, Latvia*, Lithuania*, 
Norway*, the UK*; South: Malta*; East: Poland*; West: the Netherlands*, Switzerland), 
and in Australia*.
Childhood cancers
Brain—Results are available for 66,814 children (Table 4) from 260 registries in 60 
countries (Tables 2 and 4).
For children diagnosed during 2010–2014, age-standardised five-year net survival was close 
to 80% in Denmark*, Slovakia* and Sweden*. Survival was in the range 70–79% in 17 
countries: in Canada and the US; in Costa Rica* and Puerto Rico*; in Israel* and Japan; and 
in 11 European countries (North: Finland*, Ireland*, Norway*, the UK*; South: Croatia*, 
Italy, Portugal*; West: Belgium*, France*, Germany, Switzerland*).
Survival was in the range 60–69% in 15 countries: in Argentina; in Korea*, Singapore* and 
Turkey; in 10 European countries (North: Estonia*, Latvia*, Lithuania*; South: Greece*, 
Slovenia*, Spain; East: Belarus*, Poland*, Russia; West: the Netherlands*); and in 
Australia*.
Five-year survival was below 40% in Brazil and Mexico*.
Survival trends between 2000–2004 and 2010–2014 were generally stable or increasing. 
Five-year age-standardised survival increased by 5–10% in China, Korea* and Turkey; in 6 
European countries (North: Ireland*; South: Croatia*, Italy, Portugal* West: Germany, the 
Netherlands*) and in Australia*.
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Survival increased by 10% or more in Argentina, Thailand, and 4 European countries 
(North: Denmark*, Lithuania*; East: Czech Republic*, Slovakia*).
Acute lymphoblastic leukaemia (ALL)—Results are available for 87,351 children from 
254 registries in 61 countries (Tables 2 and 4).
The global range in survival was very wide, from 50% to more than 90% (Figure 2C, web-
figures 2 and 4). For children diagnosed during 2010–2014, age-standardised five-year net 
survival was 90% or above in Puerto Rico*, in Canada and the US; in Qatar*, in 9 European 
countries (North: Denmark*, Finland*, the UK*; South: Malta*, Portugal*; West: Belgium*, 
Germany, the Netherlands*, Switzerland*), and in Australia* and New Zealand*.
Survival was in the range 80–89% in Costa Rica*, in 9 Asian countries (South: Malaysia 
(Penang), Singapore*; East: Japan, Korea*; West: Cyprus*, Israel*, Jordan*, Kuwait*, 
Turkey), and in 14 European countries (North: Estonia*, Ireland*, Latvia*, Norway*, 
Sweden*; South: Croatia*, Greece*, Italy, Spain; East: Belarus*, Czech Republic*, Poland*, 
Slovakia*; West: France*). (Table 5, Figure 2C, web-figure 2).
Five-year net survival was still below 70%, even after adjustment for the very high 
background mortality in childhood: in Brazil, Chile, Colombia, Peru and Thailand. Survival 
was below 60% in China, Ecuador and Mexico*.
In the 20-year period between 1995–1999 and 2010–2014, five-year survival increased by 
10% or more in 18 countries: in Colombia; in 8 Asian countries (South: Thailand; East: 
China, Japan, Korea*, Taiwan*; West: Cyprus*, Kuwait*, Turkey), and in 9 European 
countries (North: Finland*; Lithuania*, the UK*; South: Malta*; Portugal*, Spain; East: 
Belarus*, Bulgaria*; West: Belgium*) (web-figure 3).
Lymphoma—Results are available for 41,196 children from 257 registries in 62 countries 
(Tables 2 and 4).
Five-year age-standardised net survival was generally in the range 80–95% (Table 5, web-
figure 4).
For children diagnosed during 2010–2014, five-year survival was 90% or higher in 27 
countries: in Canada and the US; in Costa Rica* and Puerto Rico*; in 4 Asian countries 
(South: Singapore*; East: Korea*; West: Israel*, Kuwait*); in 17 European countries (North: 
Denmark*, Finland*, Ireland*, Lithuania*, Norway*, the UK*; South: Croatia*, Italy, 
Portugal*, Slovenia*, Spain; East: Poland*, Russia; West: Belgium*, France*, Germany, 
Switzerland*), and in Australia* and New Zealand*. Five-year survival was below 70% only 
in Ecuador (67%) and China (61%).
Five-year survival trends were generally rather flat over the 15 years between 2000–2004 
and 2010–2014 (web-figure 3), but survival increased by 5–10% in the US; in Korea*, 
Singapore* and Taiwan*; and in 4 European countries (North: the UK*; South: Portugal*, 
Spain; West: Germany).
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Five-year survival increased by more than 10% in Brazil; in Bulgaria*, Croatia* and 
Poland*, and by 20% or more in Slovenia* and Russia.
Discussion
CONCORD-3 updates the world-wide surveillance of cancer survival to 2014. It is the 
largest and most up-to-date study of international cancer survival trends. It includes 
individual data for over 37.5 million patients diagnosed with cancer during the 15-year 
period 2000–2014. Data were provided by over 320 population-based cancer registries in 71 
countries and territories, in 47 of which the data covered 100% of the population. The 
participating countries were home to 67% of the world’s population in 2014 (7.3 billion).27 
The registries record all cancers diagnosed in a combined population of almost one billion 
people, or 14% of the world population.
Internationally comparable survival trends are now available for 18 cancers that collectively 
represent 75% of all cancers diagnosed world-wide every year.
We used a similar design and statistical methods to those used in CONCORD-26, to enable 
evaluation of survival trends for 10 cancers over the 20-year period 1995–2014. World-wide 
survival trends are also available for the first time for melanoma of the skin and cancers of 
the oesophagus and pancreas in adults, and for brain tumours and lymphomas in both adults 
and children.
Five-year survival has been recognised by clinicians as an index of the effectiveness of the 
treatment of cancer for more than 60 years. When applied to hospital case series, it has often 
been labelled as the “five-year cure rate”, because “with so mortal a disease as cancer, those 
who survive for this length of time can be considered cured.”44 Five-year survival has 
increased for many cancers since the 1950s, but it remains a widely used benchmark, even 
though it cannot be directly interpreted as the proportion of patients who are cured.45
Population-based cancer survival is increasingly recognised as a key indicator of the overall 
effectiveness of the health systems in managing care and treatment for all cancer patients.
46,47
 Other outcome measures with applications in cancer control include the number of 
avoidable premature deaths,48–53 person-years of life lost,54,55 disability-adjusted life-years 
lost,56 and levels of population “cure”.57–61 Cancer survival has applications to cancer 
control and health policy at the state, national and global levels, in both high-income and 
low-income countries.62
In some countries, population-based cancer survival estimates may be considered as too 
high, potentially discouraging ministerial action to improve survival. Estimates showing 
ethnic or regional variation in cancer survival may be politically sensitive. Survival estimates 
may also be considered too low, if they are seen as a reflection of clinical competence.63
Low levels of survival in a country or region should not be interpreted as an indicator of the 
competence of the health professionals who work there. Population-based survival reflects 
the overall effectiveness of the health service, which depends on much wider issues than the 
competence of any individual doctor or team.64–66
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The Organisation for Economic Co-operation and Development (OECD) recently concluded 
from the wide international variation in cancer survival that many countries could do better 
in cancer control.64 It recommended a national cancer plan, adequate funding, and initiatives 
for early detection and rapid access to high-quality treatment.64 OECD also recommended 
improving the quality of cancer data to support monitoring improvements in survival.
From 2017, OECD will include age-standardised five-year net survival estimates from the 
CONCORD programme for colorectal and breast cancers in adults and acute lymphoblastic 
leukaemia in children among the indicators of healthcare quality in its biennial and online 
publications Health at a Glance.67 This is formal recognition of the global coverage, 
methodological rigour and international comparability of the CONCORD survival estimates, 
which will now contribute to the comparative evaluation of health systems performance in 
48 countries, including all OECD Member countries. The findings will also help monitor 
progress toward the overarching goal of the 2013 World Cancer Declaration, to achieve 
major improvements in cancer survival by 2020.68
We carried out extensive checks on data quality, and liaised with the cancer registries to 
resolve problems. Many registries told us that the CONCORD data quality reports helped 
them improve their data. Some centres in Nigeria and India have modified hospital 
admission forms or pathology request forms to capture telephone numbers of patients and 
their next of kin, to facilitate follow-up of their patients. We extended the data quality 
control programs and the reports. Rectifying errors or inconsistencies in the data often led to 
extensive discussion with registry staff, and re-submission of data with higher quality.
The quality and completeness of cancer registration data and follow-up vary between 
countries, and this can affect the comparability of survival estimates. We have provided 
extensive documentation of data quality with standard indicators69 for each cancer and each 
cancer registry (web-table 2). Survival figures and trends should be interpreted alongside 
those indicators. The overall proportion of tumour records excluded because of incomplete 
dates (0.5%), or for other reasons such as missing vital status (1.2%), has remained very low. 
The overall proportion of cancers registered solely from a death certificate (DCO), or 
detected at autopsy, dropped to 2.9%, but it remains high in some countries where cancer 
registration processes are slow, especially for the more rapidly lethal cancers of the 
oesophagus, pancreas and liver. These are well-known issues in population-based cancer 
registration. DCOs can be included in cancer incidence statistics under certain assumptions, 
but they reflect some under-estimation of incidence.69 By contrast, DCO cases must be 
excluded from survival analyses, because the patient’s survival time is unknown. This tends 
to inflate survival estimates.70
In some countries, survival estimates have fluctuated or declined in successive calendar 
periods; this is likely to reflect improvements in the completeness of cancer registration data 
and in the completeness of follow-up for vital status. In Jordan, for example, linkage with 
the national death index has been insufficient because only about 70% of deaths are 
certified. Survival estimates were very high for stomach and colorectal cancers and they are 
flagged as less reliable. One recent hospital-based survival study from Jordan71 suggests that 
colon cancer survival in Jordan is much lower than the estimates we have obtained. Other 
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countries with incomplete death registration, such as India, follow up their patients actively 
to determine their vital status.
Despite the problems, we believe these findings represent the best that can be achieved with 
the available coverage and quality of cancer registration systems and vital statistics systems 
world-wide. The quality of diagnostic evidence is generally high. Data quality has improved 
in many countries, with increasing proportions of cases for which the diagnosis was 
confirmed by pathology, imaging or biomarkers, and reduction in the proportion of patients 
lost to follow-up. Pathological confirmation of a primary, invasive malignancy was available 
for more than 94% of all patients. The proportion varies widely between countries and for 
different cancers, but the evidence supporting a cancer diagnosis in routine cancer registry 
data is far more precise and definitive than for the cause(s) of death recorded on death 
certificates, from which mortality statistics are obtained.72–75
In some cases, especially in South America, the improvement in data quality is reflected in 
survival estimates that are actually lower than those previously published,6 with fewer death-
certificate-only registrations and more complete follow-up. In Brazil, for example, 
improvement in the quality and completeness of the national death registry (Sistema de 
Informações sobre Mortalidade, or SIM) during 2000–201576 has enabled more complete 
linkage of death records with the cancer registries. In several countries, survival estimates 
that were flagged as less reliable in CONCORD-2 are now more reliable, even if the survival 
estimates are lower.
To estimate the global burden of cancer incidence, assumptions are required where there are 
no cancer registries, usually by modelling incidence and mortality data from other countries 
in the same world region.2,77 By contrast, we have made no attempt to model cancer survival 
in countries or regions where population-based cancer registration data were not available. 
Cancer survival cannot be estimated or modelled by assuming that the health system is as 
effective as in some other country where population-based survival estimates are available. 
On the contrary, cancer survival estimates are required to assess the overall effectiveness of a 
country’s health system in the first place. For that, cancer registries are essential.
The survival estimates reported here are derived directly from the records of individual 
patients diagnosed with cancer, and from long-term follow-up to ascertain their vital status, 
followed by standardised quality control and central analysis. This is not a compilation of 
published reports or a meta-analysis.
Survival for most cancers remains among the highest in the world in the US, Canada, 
Australia and New Zealand, and in Finland, Iceland, Norway and Sweden. Publications that 
showed surprisingly low survival in Denmark78,79 prompted national cancer plans in 2000, 
2005 and 2011, focused on early diagnosis and treatment to improve survival.80 From 2007, 
cancer was regarded as an acute life-threatening disease, leading to accelerated cancer-
specific pathways for diagnosis, with public monitoring of hospitals‟ compliance with 
waiting times. For most cancers, survival has increased more in Denmark, and survival has 
nearly caught up with the other Nordic countries.81,82 Norway and Sweden have now 
established similar cancer patient pathways.
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Cancer survival trends are generally increasing, even for some of the more lethal cancers. In 
some countries, survival increased up to 5% for liver, pancreas and lung cancers. For 
example, survival trends for liver cancer were generally stable during 1995 to 2014, but 
survival increased by more than 10% in Korea, Singapore and Norway.
However, where five-year survival remains extremely low in all countries (e.g. pancreatic 
cancer, range 5–15%), international efforts will be required to understand risk factors and 
improve prevention, but also to promote earlier diagnosis and better treatment, to improve 
outcomes. International comparisons of survival for pancreatic cancer include both ductal 
adenocarcinomas and the less common neuroendocrine tumours, for which survival is 
generally higher. The impact of variation in these proportions will require detailed analysis.
Age-standardised five-year net survival for stomach cancer was below 30% in most 
countries, but high in Korea (69%) and Japan (60%), where it increased by up to 10% 
between 2000–2004 and 2010–2014. This pattern is likely to be associated with 
longstanding population-based endoscopic screening programmes for early detection of 
gastric and oesophageal cancers, which are very common. Population awareness is high. 
Gastric cancer screening in Korea started in 1999 as part of the National Cancer Screening 
Programme, with biennial contrast radiology or endoscopy for adults aged 40 years or over.
83
 This doubles the chances of early diagnosis compared with unscreened patients.84 
Endoscopic resection with clear margins may be curative in stage I oesophageal and gastric 
cancers (up to 2cm diameter), if invasion is limited to the superficial submucosa, and there is 
no lymphovascular invasion.85 By contrast, where gastric cancer is a less serious public 
health issue, and in the absence of screening, it is often diagnosed at an advanced stage. In 
Russia in 2015, for example, stomach cancer was most often diagnosed in stage IV (40%), 
and open laparotomy, chemotherapy and radiation were required for 22% and 25% of cases 
in stages II and III, respectively. Screening for oesophageal and gastric cancers should be 
considered as part of national cancer control plans where these tumours are common, or in 
high-risk populations.86
Survival trends for colorectal cancer were generally flat, or increasing, over the 20 years 
1995–2014. Survival for rectal cancer was very similar among the Nordic countries (64–
65%) and among most southern European countries (61%).
Survival from melanoma of the skin is generally lower in Asian populations than the rest of 
the world. One explanation may be lower public awareness, because melanoma is less 
common, but it may also be that Asian patients typically present with more advanced 
disease, and with acral lentiginous melanoma. This is one of the more lethal sub-types, and 
it is more common than in western populations.87 In the CONCORD data (not shown), acral 
lentiginous melanoma represents 1.2% of all skin melanomas, and 1% in Europe and North 
America, but 6% in Asia.
The increasing trend in five-year net survival from breast cancer during the 15 years 1995–
2009 has continued in most countries up to 2014, but it remains lower in India, Thailand and 
several of the eastern European countries.
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Five-year survival from cervical cancer has increased in several European and Asian 
countries. However, survival may even decline following an increase in diagnostic activity. 
In North America and Oceania, survival is lower than in other countries, due to more 
intensive screening programmes that detect precancerous cells and in situ tumours. These 
can be cured with a range of simple techniques, reducing cancer incidence by removal of the 
more indolent malignancies, while the more aggressive tumours are less likely to be detected 
by screening.
Some of the global range in survival may be attributable to differences in the intensity of 
diagnostic activity, and to over-diagnosis from the detection of very small or less aggressive 
tumours, that would not have been expected to lead to symptomatic diagnosis or death in the 
patient’s expected lifetime.88,89 As in CONCORD-2,6 we were unable to use the proportion 
of in situ cancers to compare the intensity of diagnostic activity for solid tumours. Some 
registries still do not record in situ tumours, while other registries did not submit data for in 
situ tumours.
Since screening programmes are only available in wealthier countries, mainly in selected age 
ranges for cancers of the breast, cervix and colon, the extent of over-diagnosis seems 
unlikely to have a large impact on the global range of cancer survival. Measures of over-
diagnosis are only available at the population level, so their application in the interpretation 
of cancer survival patterns would be limited to ecological comparisons, as for GDP or total 
national expenditure on health. By contrast, data on stage at diagnosis are available for 
individuals. Analyses of the distribution of stage at diagnosis and stage-specific survival will 
be expected to provide further insight into international variation in cancer survival.90,91
Survival from the adult leukaemias up to 2009 in Asian populations was much lower than in 
Europe, North America and Oceania.6 One possible explanation was the relative rarity in 
Asian populations of chronic lymphocytic leukaemia (CLL), which has a relatively good 
prognosis in western populations. However, survival from CLL is also much lower in Taiwan 
than in the US,92 and the findings reported here also show that survival is generally lower in 
south-east Asia than in other countries in adults, for both myeloid and lymphoid 
malignancies. The difference between the median of the survival estimates for Asian 
populations and for other populations narrowed between 2000–2004 and 2010–2014, for 
both myeloid and lymphoid malignancies. In most south-east Asian countries, survival for 
myeloid malignancies has risen by 5–14%, and by 10% or more for lymphoid malignancies.
Survival from brain tumours in children is generally higher than for adults, but the global 
range is much more pronounced. Some of the international variation in survival from brain 
tumours may be due to variation in the proportion that are benign. Where benign tumours 
are registered, the proportion typically ranges up to 10–15% in both adults and children 
(data not shown). However, some registries do not record benign brain tumours, and this 
varies both between and within countries. For example, benign brain tumours are not 
registrable in New South Wales or Western Australia (45% of the national population), 
whereas they comprise up to 5% of brain tumours in Queensland and Victoria, with a similar 
combined population. The impact of morphology, behaviour and grade on international 
patterns of brain tumour survival needs further research.
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International variation in survival for childhood lymphoma was less marked than for 
childhood ALL. The marked increase in five-year survival among children diagnosed with 
lymphoma in Brazil (from 69% in 2000–2004 to 88% in 2010–2014) may reflect a real 
improvement in diagnosis and treatment.
Cancer kills more than 100,000 children every year, mainly in low- and middle-income 
countries,93 where access to health services is often poor, and abandonment of treatment is a 
major problem.94,95 Reliable data on the cost and the effectiveness of health services in 
managing childhood cancer are scarce, yet such data would offer important evidence for 
countries to compare the impact of their strategies for managing children with cancer.96 
Survival estimates published here for children diagnosed with a brain tumour, lymphoma or 
leukaemia will be deployed in a Lancet Oncology Commission on childhood cancer, 
designed to establish the evidence for investing in effective interventions to reduce the 
burden of childhood cancer.
Survival trends could not be systematically assessed in Africa. In some registries, the 
proportion of records with incomplete dates ranged up to 40%. Survival estimates for acute 
lymphoblastic leukaemia in Algeria were less reliable because follow-up was less than 5 
years for more than 50% of children. For Nigeria (Ibadan) and South Africa (Eastern Cape), 
data were only available for 12 and 7 children, respectively, and survival was not estimated. 
Where survival could be estimated with some confidence, it was often very low, although 
survival in Mauritius was generally higher. In Nigeria, for example, there are no trained 
medical oncologists. Some haematologists and paediatric oncologists administer 
chemotherapy, but the availability of chemotherapy is limited in both the public and private 
sectors, and most patients pay out of their own pocket. The cost is prohibitive. These factors 
frequently disrupt treatment and may lead to poor outcomes.
To control for background mortality by age and sex, we updated the library of life tables for 
1995–201097 by country, registry, race (selected countries) and calendar year to 2014, with a 
statistical summary for each set of life tables. It will shortly be available from the Cancer 
Survival Group web-site. In some countries, it has become more difficult to obtain the death 
and population counts required to construct life tables.
Survival estimates from CONCORD-2 for cancers of the breast and cervix were used in a 
recent Lancet Series on Women‟s Cancers,98,99 to help describe trends in the global burden 
of these cancers. Survival for the 2 million women diagnosed with one of these cancers 
every year remains highly dependent on the country in which they live. The Series 
highlighted the urgent need for more cost-effective cancer control strategies in low- and 
middle-income countries.
The global economic cost of treating the 12.9 million new cancer patients diagnosed 
worldwide in 2009 was estimated at US$286 billion.100 The costs of cancer treatment and 
care in the US alone were projected to rise by 23% between 2010 and 2020, from US$128 to 
US$158 billion, solely on the basis of demographic change, and with fixed incidence rates, 
survival probabilities and treatment costs.101 If treatment costs rise by 2% a year, the overall 
cost of treatment and care – in the US alone – could reach US$173 billion, a 39% increase. 
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If incidence rates continue to rise, the prevalence of cancer survivors will increase further, 
triggering still further increase in the costs of care.
On the basis of these figures, it seems plausible that the global cost of cancer treatment and 
care in 2017 must already be substantially higher than US$300 billion a year. Spiralling 
costs102 threaten the viability of health systems and national economies. Where universal 
health coverage has not been achieved, the out-of-pocket costs can lead to financial 
catastrophe for individuals and families.3
The indirect economic costs associated with premature death and lost productivity from the 
growing cancer burden have been estimated at US$1.16 trillion a year,3 or approaching 2% 
of global GDP.103 It has been argued that the increasing cost and complexity of cancer 
treatment requires a radical shift in cancer policy, in which inequitable access to affordable 
cancer treatment ceases to be politically acceptable.104 Population-based data on cancer 
survival trends that are comparable within and between countries are part of the evidence 
base needed to drive such a policy shift.
With this background, cancer registries can be seen as efficient public health instruments, 
producing a continuous stream of valuable information for cancer control at low cost.105 In 
Europe in 2013, the average cost per patient registered, including the registry’s costs for 
personnel, IT and infrastructure, was €51 (range €6–213; US$59, range US$7–252). This is 
less than the typical cost of a chest X-ray. For the population as a whole, the cost was less 
than €1 (US$1.18) per person per year.
In 2015, the UN introduced 17 Sustainable Development Goals (SDG), aiming to end 
poverty, protect the planet, and ensure prosperity for all.106 Goal 3 is “to ensure healthy lives 
and promote well-being for all at all ages”. For this goal, target 3.4 is to reduce “premature” 
mortality (among persons aged 30–70 years) from non-communicable diseases, including 
cancer, by one-third, by 2030, through prevention and treatment.107 The challenge will be to 
secure overall improvements in health outcomes that do not lead to wider inequalities.108
Achieving the SDG target of a one-third reduction in premature mortality by 2030 clearly 
requires more effective prevention, to reduce cancer incidence. However, the 15-year time-
frame is short, and achieving the target will also require investment in more effective health 
systems, to improve survival.46
WHO recently called for the development of population-based cancer registries, so that 
effective policies for cancer control can be founded on accurate data.3 It also called for 
stronger civil registration and vital statistics systems. These systems support the basic 
functions of government and enable measurement of progress towards development goals,
109
 yet population coverage is poor in low- and middle-income countries, and closely related 
to gross national income.110
Most cancer registries establish the vital status of all patients registered with cancer by 
linkage with vital statistics data (regional or national death indexes). This is known as 
passive follow-up, although many registries also contact patients’ doctors or families directly 
(active follow-up). For passive follow-up to work, efficient civil registration systems that 
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capture information on all deaths are required. This underpins the estimation of population-
based cancer survival, even though active follow-up can be effective in some populations. 
Yet cancer registries report increasing difficulty in linking their databases to regional or 
national death indexes. Legal and administrative obstacles and technical difficulties have all 
been reported. Some national authorities holding death indexes clearly give very low priority 
to such linkages.
These problems undermine the public health purpose of cancer registration. Of the 400 
operational registries we contacted, more than 20 were unable to follow up all registered 
patients to ascertain their vital status. This problem arose in 16 countries, including some 
high-income countries. Some registries were unable to provide survival data at all. In 
Canada, for example, national coverage of cancer survival statistics was achieved for the first 
time in CONCORD-2,6 with data from all 13 provinces and territories for 1995–2009, but 
several jurisdictions were unable to participate in CONCORD-3 because of legal or 
administrative difficulties in linking their cancer registry with death records. For 8 countries 
that expressed interest or even submitted data, these difficulties meant that no survival 
estimates could be produced at all: Bénin, Bosnia-Herzegovina, Indonesia, Panama, the 
Philippines, Saudi Arabia, Serbia and Tunisia.
It is crucial for national and regional governments to recognise that population-based cancer 
registries are key policy tools, both to monitor the impact of cancer prevention strategies, 
and to evaluate the effectiveness of the health system for all patients diagnosed with cancer. 
All registries, especially those in low- and middle-income countries, need to be given 
adequate resources to register all patients with cancer in timely fashion, the right to access 
up-to-date national and regional death records to establish their vital status, and the 
legislative stability to operate efficiently over the long term.111
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Manizales); DM Jurado, MC Yépez Chamorro (Registro Poblacional de Cáncer del 
Municipio de Pasto); Costa Rica: S Delgado, M Ramirez (National Registry of Tumors, 
Costa Rica); Cuba: YH Galán Alvarez, P Torres (Registro Nacional de Cáncer de Cuba); 
Ecuador: F Martínez-Reyes (Cuenca Tumor Registry); L Jaramillo, R Quinto (Guayaquil 
Cancer Registry); J Castillo (Loja Cancer Registry); M Mendoza (Manabí Cancer Registry); 
P Cueva, JG Yépez (Quito Cancer Registry); France: B Bhakkan, J Deloumeaux (Registre 
des cancers de la Guadeloupe); C Joachim, J Macni (General Cancer Registry of 
Martinique); Mexico: R Carrillo, J Shalkow Klincovstein (Centro Nacional para la Salud de 
la Infancia y la Adolescencia); R Rivera Gomez (Registro Poblacional de Cancer Region 
Fronteriza Norte de Mexico Zona Tijuana); Peru: E Poquioma (Lima Metropolitan Cancer 
Registry); Puerto Rico: G Tortolero-Luna, D Zavala (Puerto Rico Central Cancer Registry); 
Uruguay: R Alonso, E Barrios (Registro Nacional de Cáncer)
America (North)—Canada: A Eckstrand, C Nikiforuk (Alberta Cancer Registry); RR 
Woods (British Columbia Cancer Registry); G Noonan, D Turner* (Manitoba Cancer 
Registry); E Kumar, B Zhang (New Brunswick Provincial Cancer Registry); FR McCrate, S 
Ryan (Newfoundland & Labrador Cancer Registry); M MacIntyre, N Saint-Jacques (Nova 
Scotia Cancer Registry); DE Nishri* (Ontario Cancer Registry); CA McClure, KA Vriends 
(Prince Edward Island Cancer Registry); S Kozie, H Stuart-Panko (Saskatchewan Cancer 
Agency); USA: T Freeman, JT George (Alabama Statewide Cancer Registry); JT 
Brockhouse, DK O’Brien (Alaska Cancer Registry); A Holt (Arkansas Central Cancer 
Registry); L Almon (Metropolitan Atlanta Registry); S Kwong, C Morris (California State 
Cancer Registry); R Rycroft (Colorado Central Cancer Registry); L Mueller, CE Phillips 
(Connecticut Tumor Registry); H Brown, B Cromartie (Delaware Cancer Registry); AG 
Schwartz, F Vigneau (Metropolitan Detroit Cancer Surveillance System); GM Levin, B 
Wohler (Florida Cancer Data System); R Bayakly (Georgia Cancer Registry); KC Ward 
(Georgia Cancer Registry; Metropolitan Atlanta Registry); SL Gomez, M McKinley 
(Greater Bay Area Cancer Registry); R Cress (Cancer Registry of Greater California); MD 
Green, K Miyagi (Hawaii Tumor Registry); CJ Johnson (Cancer Data Registry of Idaho); LP 
Ruppert (Indiana State Cancer Registry); CF Lynch (State Health Registry of Iowa); B 
Huang, TC Tucker* (Kentucky Cancer Registry); D Deapen, L Liu (Los Angeles Cancer 
Surveillance Program); MC Hsieh, XC Wu (Louisiana Tumor Registry); M Schwenn (Maine 
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Cancer Registry); ST Gershman, RC Knowlton (Massachusetts Cancer Registry); G 
Alverson, GE Copeland (Michigan State Cancer Surveillance Program); S Bushhouse 
(Minnesota Cancer Surveillance System); DB Rogers (Mississippi Cancer Registry); J 
Jackson-Thompson (Missouri Cancer Registry and Research Center); D Lemons, HJ 
Zimmerman (Montana Central Tumor Registry); M Hood, J Roberts-Johnson (Nebraska 
Cancer Registry); JR Rees, B Riddle (New Hampshire State Cancer Registry); KS Pawlish, 
A Stroup (New Jersey State Cancer Registry); C Key, C Wiggins (New Mexico Tumor 
Registry); AR Kahn, MJ Schymura (New York State Cancer Registry); S Radhakrishnan, C 
Rao (North Carolina Central Cancer Registry); LK Giljahn, RM Slocumb (Ohio Cancer 
Incidence Surveillance System); RE Espinoza, F Khan (Oklahoma Central Cancer Registry); 
KG Aird, T Beran (Oregon State Cancer Registry); JJ Rubertone, SJ Slack (Pennsylvania 
Cancer Registry); L Garcia, DL Rousseau (Rhode Island Cancer Registry); TA Janes, SM 
Schwartz (Seattle Cancer Surveillance System); SW Bolick, DM Hurley (South Carolina 
Central Cancer Registry); MA Whiteside (Tennessee Cancer Registry); P Miller-Gianturco, 
MA Williams (Texas Cancer Registry); K Herget, C Sweeney (Utah Cancer Registry); AT 
Johnson (Vermont Cancer Registry); MB Keitheri Cheteri, P Migliore Santiago (Washington 
State Cancer Registry); SE Blankenship, S Farley (West Virginia Cancer Registry); R 
Borchers, R Malicki (Wisconsin Department of Health Services); JR Espinoza, J Grandpre 
(Wyoming Cancer Surveillance Program); HK Weir*, R Wilson (Centers for Disease 
Control and Prevention); BK Edwards*, A Mariotto (National Cancer Institute)
Asia—China: Y Lei, N Wang (Beijing Cancer Registry); JS Chen, Y Zhou (Changle City 
Cancer Registry); YT He, GH Song (Cixian Cancer Registry); XP Gu (Dafeng County 
Center for Disease Control and Prevention); D Mei, HJ Mu (Dalian Centers for Disease 
Prevention and Control); HM Ge, TH Wu (Donghai County Center for Disease Prevention 
and Control); YY Li, DL Zhao (Feicheng County Cancer Registry); F Jin, JH Zhang (Ganyu 
Center for Disease Prevention and Control); FD Zhu (Guanyun Cancer Registry); Q Junhua, 
YL Yang (Haimen Cancer Registry); CX Jiang (Haining City Cancer Registry); W Biao, J 
Wang (Jianhu Cancer Registry); QL Li (Jiashan County Cancer Registry); H Yi, X Zhou 
(Jintan Cancer Registry); J Dong, W Li (Lianyungang Center for Disease Prevention and 
Control); FX Fu, SZ Liu (Linzhou Cancer Registry); JG Chen, J Zhu (Qidong County 
Cancer Registry); YH Li, YQ Lu (Sihui Cancer Registry); M Fan, SQ Huang (Taixing 
Cancer Registry); GP Guo, H Zhaolai (Cancer Institute of Yangzhong City); K Wei 
(Zhongshan City Cancer Registry); WQ Chen*, H Zeng (The National Cancer Center); 
Cyprus: AV Demetriou (Cyprus Cancer Registry); Hong Kong: WK Mang, KC Ngan (Hong 
Kong Cancer Registry); India: AC Kataki, M Krishnatreya (Guwahati Cancer Registry); PA 
Jayalekshmi, P Sebastian (Karunagappally Cancer Registry); A Nandakumar* (National 
Centre for Disease Informatics and Research); Iran: R Malekzadeh, G Roshandel (Golestan 
Population-based Cancer Registry); Israel: L Keinan-Boker, BG Silverman (Israel National 
Cancer Registry); Japan: H Ito, H Nakagawa (Aichi Cancer Registry); M Sato, F Tobori 
(Akita Prefectural Cancer Registry); I Nakata, N Teramoto (Ehime Prefectural Cancer 
Registry); M Hattori, Y Kaizaki (Fukui Cancer Registry); F Moki (Gunma Prefectural 
Cancer Registry); H Sugiyama, M Utada (Hiroshima Prefecture Cancer Registry); M 
Nishimura, K Yoshida (Hyogo Prefectural Cancer Registry); K Kurosawa, Y Nemoto 
(Ibaraki Prefectural Cancer Registry); H Narimatsu, M Sakaguchi (Kanagawa Cancer 
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Registry); S Kanemura (Miyagi Prefectural Cancer Registry); M Naito, R Narisawa (Niigata 
Prefecture Cancer Registry); I Miyashiro, K Nakata (Osaka Cancer Registry); S Sato, M 
Yoshii (Saga Prefectural Cancer Registry); I Oki (Tochigi Prefectural Cancer Registry); N 
Fukushima, A Shibata (Yamagata Prefectural Cancer Registry); K Iwasa, C Ono (Yamanashi 
Cancer Registry); T Matsuda* (National Cancer Center); Jordan: O Nimri (Jordan National 
Cancer Registry); Korea: KW Jung, YJ Won (Korea Central Cancer Registry); Kuwait: E 
Alawadhi, A Elbasmi (Kuwait Cancer Registry); Malaysia: A Ab Manan (Malaysia 
National Cancer Registry); F Adam (Penang Cancer Registry); Mongolia: E Sanjaajmats, U 
Tudev (Cancer Registry of Mongolia); C Ochir (Mongolian National University of Medical 
Sciences); Qatar: AM Al Khater, MM El Mistiri (Qatar Cancer Registry); Singapore: GH 
Lim, YY Teo (Singapore Cancer Registry); Taiwan: CJ Chiang, WC Lee (Taiwan Cancer 
Registry); Thailand: R Buasom, S Sangrajrang (Bangkok Cancer Registry); S Kamsa-ard, S 
Wiangnon (Khon Kaen Provincial Cancer Registry); K Daoprasert, D Pongnikorn (Lampang 
Cancer Registry; Lamphun Cancer Registry); A Leklob, S Sangkitipaiboon (Lopburi Cancer 
Registry); SL Geater, H Sriplung (Songkhla Cancer Registry); Turkey: O Ceylan, I Kög 
(Ankara Cancer Registry); O Dirican (Antalya Cancer Registry); T Köse (Bursa Cancer 
Registry); T Gurbuz (Edirne Cancer Registry); FE Karaşahin, D Turhan (Erzurum Cancer 
Registry Center); U Aktaş, Y Halat (Eskişehir Cancer Registry); S Eser, CI Yakut (Izmir 
Cancer Registry); M Altinisik, Y Cavusoglu (Samsun Cancer Registry); A Türkköylü, N 
Üçüncü (Trabzon Cancer Registry) Europe—Austria: M Hackl (Austrian National Cancer 
Registry); Belarus: AA Zborovskaya (Belarus Childhood Cancer Subregistry); OV 
Aleinikova (Belarusian Research Center for Pediatric Oncology, Hematology and 
Immunology); Belgium: K Henau, L Van Eycken (Belgian Cancer Registry); Bulgaria: Z 
Valerianova, MR Yordanova (Bulgarian National Cancer Registry); Croatia: M Šekerija 
(Croatian National Cancer Registry); Czech Republic: L Dušek, M Zvolský (Czech National 
Cancer Registry); Denmark: G Engholm, H Storm* (Danish Cancer Society); Estonia: K 
Innos, M Mägi (Estonian Cancer Registry); Finland: N Malila, K Seppä (Cancer Society of 
Finland); France: J Jégu, M Velten (Bas-Rhin General Cancer Registry); E Cornet, X 
Troussard (Registre Régional des Hémopathies Malignes de Basse Normandie); AM 
Bouvier (Registre Bourguignon des Cancers Digestifs); AV Guizard (Registre Général des 
Tumeurs du Calvados); V Bouvier, G Launoy (Registre des Tumeurs Digestives du 
Calvados); P Arveux (Breast cancers registry of Côte-d’Or France); M Maynadié, M 
Mounier (Hémopathies Malignes de Côte d’Or); AS Woronoff (Doubs and Belfort Territory 
General Cancer Registry); M Daoulas, M Robaszkiewicz (Finistère Cancer Registry); J 
Clavel, S Goujon (French National Registry of Childhood Hematopoietic Malignancies); B 
Lacour (National Registry of Childhood Solid Tumors); I Baldi, C Pouchieu (Gironde 
Registry of Primary Central Nervous System Tumors); B Amadeo, G Coureau (General 
Cancer Registry of Gironde Department); A Monnereau (Registre des Hémopathies 
Malignes de la Gironde; French Network of Cancer Registries (FRANCIM)); S Orazio 
(Registre des Hémopathies Malignes de la Gironde); PM Preux, F Rharbaoui (Registre 
Général des Cancers de Haute-Vienne); E Marrer (Haut-Rhin Cancer Registry); B Trétarre 
(Registre des Tumeurs de l’Hérault); M Colonna, P Delafosse (Registre du Cancer du 
Département de l’Isère); K Ligier, S Plouvier (Registre Général des Cancers de Lille et de sa 
Region); A Cowppli-Bony, F Molinié (Loire-Atlantique-Vendée Cancer Registry); S Bara 
(Manche Cancer Registry); O Ganry, B Lapôtre-Ledoux (Registre du Cancer de la Somme); 
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P Grosclaude (Tarn Cancer Registry); N Bossard, Z Uhry (Hospices Civils de Lyon); F 
Bray*, M Piñeros* (International Agency for Research on Cancer); J Estève (Université 
Claude Bernard, Lyon); Germany: R Stabenow, H Wilsdorf-Köhler (Common Cancer 
Registry of the Federal States); A Eberle, S Luttmann (Bremen Cancer Registry); I Löhden, 
AL Nennecke (Hamburg Cancer Registry); J Kieschke, E Sirri (Epidemiological Cancer 
Registry of Lower Saxony); K Emrich, SR Zeissig (Rhineland Palatinate Cancer Registry); 
B Holleczek (Saarland Cancer Registry); N Eisemann, A Katalinic (Schleswig-Holstein 
Cancer Registry); Gibraltar: RA Asquez, V Kumar (Gibraltar Cancer Registry); Greece: E 
Petridou (Nationwide Registry for Childhood Haematological Malignancies and Solid 
Tumors); Iceland: EJ Ólafsdóttir, L Tryggvadóttir (Icelandic Cancer Registry, Icelandic 
Cancer Society); Ireland: K Clough-Gorr, PM Walsh (National Cancer Registry Ireland); H 
Sundseth* (European Institute of Women‟s Health); Italy: G Mazzoleni, F Vittadello 
(Registro Tumori Alto Adige); E Coviello, F Cuccaro (Registro Tumori Puglia – Sezione 
ASL BT); R Galasso (Registro Tumori di Basilicata); G Sampietro (Registro Tumori di 
Bergamo); A Giacomin† (Piedmont Cancer Registry Provinces of Biella and Vercelli); M 
Magoni (Registro Tumori Dell’ASL Di Brescia); A Ardizzone (Registro Tumori Brindisi); A 
D’Argenzio (Caserta Cancer Registry); M Castaing, G Grosso (Integrated Cancer Registry 
of Catania-Messina-Siracusa-Enna); AM Lavecchia, A Sutera Sardo (Registro Tumori 
Catanzaro); G Gola (Registro Tumori della Provincia di Como); L Gatti, P Ricci (Registro 
Tumori Cremona; Registro Tumori Mantova); S Ferretti (Registro Tumori della Provincia di 
Ferrara); D Serraino, A Zucchetto (Registro Tumori del Friuli Venezia Giulia); MV Celesia, 
RA Filiberti (Registro Tumori Regione Liguria); F Pannozzo (Registro Tumori della 
Provincia di Latina); A Melcarne, F Quarta (Registro Tumori Della Provincia Di Lecce 
Sezione RTP); AG Russo (Registro Tumori Milano); G Carrozzi, C Cirilli (Registro Tumori 
della Provincia di Modena); L Cavalieri d’Oro, M Rognoni (Registro Tumori di Monza e 
Brianza); M Fusco, MF Vitale (Registro Tumori della ASL Napoli 3 Sud); M Usala (Nuoro 
Cancer Registry); R Cusimano, W Mazzucco (Registro Tumori di Palermo e Provincia); M 
Michiara, P Sgargi (Registro Tumori della Provincia di Parma); L Boschetti (Cancer 
Registry of the province of Pavia); E Borciani, P Seghini (Registro Tumori Piacenza); MM 
Maule, F Merletti (Piedmont Childhood Cancer Registry); R Tumino (Registro Tumori della 
Provincia di Ragusa); P Mancuso, M Vicentini (Registro Tumori Reggio Emilia); T Cassetti, 
R Sassatelli (Reggio Emilia Cancer Registry (Pancreas)); F Falcini, S Giorgetti (Registro 
Tumori della Romagna); AL Caiazzo, R Cavallo (Registro Tumori Salerno); R Cesaraccio, 
DR Pirino (Registro Tumori della Provincia di Sassari); ML Contrino, F Tisano (Registro 
Tumori Siracusa); AC Fanetti, S Maspero (Registro Tumori della Provincia di Sondrio); S 
Carone, A Mincuzzi (Registro Tumori Taranto); G Candela, T Scuderi (Registro Tumori 
Trapani); MA Gentilini, S Piffer (Registro Tumori Trento); S Rosso (Piedmont Cancer 
Registry); A Barchielli, A Caldarella (Registro Tumori della Regione Toscana); F Bianconi, 
F Stracci (Registro Tumori Umbro di Popolazione); P Contiero, G Tagliabue (Registro 
Tumori Lombardia, Provincia di Varese); M Rugge, M Zorzi (Registro Tumori Veneto); S 
Beggiato, A Brustolin (Registro Tumori Della Provincia Di Viterbo); F Berrino*, G Gatta, M 
Sant* (Fondazione IRCCS Istituto Nazionale dei Tumori); C Buzzoni, L Mangone (Italian 
Association of Cancer Registries (AIRTUM)); R Capocaccia*, R De Angelis (National 
Centre for Epidemiology); R Zanetti* (International Association of Cancer Registries; 
Piedmont Cancer Registry); Latvia: A Maurina, S Pildava (Latvian Cancer Registry); 
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Lithuania: N Lipunova, I Vincerževskienė (Lithuanian Cancer Registry); Malta: D Agius, 
N Calleja (Malta National Cancer Registry); Netherlands: S Siesling, O Visser (Netherlands 
Cancer Registry, IKNL); Norway: S Larønningen, B Møller (The Cancer Registry of 
Norway); Poland: A Dyzmann-Sroka, M Trojanowski (Greater Poland Cancer Registry); S 
Góźdź, R Mężyk (Holy Cross Cancer Registry); T Mierzwa (Kuiavian-Pomeranian Cancer 
Registry); L Molong, J Rachtan (Lesser Poland Cancer Registry); S Szewczyk (Łódź Cancer 
Registry); J Błaszczyk, K Kępska (Lower Silesian Cancer Registry); B Kościańska (Lublin 
Cancer Registry); K Tarocińska (Lubush Cancer Registry); M Zwierko (Mazovian Cancer 
Registry); K Drosik (Opole Cancer Registry); KM Maksimowicz, E Purwin-Porowska 
(Podlahian Cancer Registry); E Reca, J Wójcik-Tomaszewska (Pomeranian Cancer 
Registry); A Tukiendorf (Silesian Cancer Registry); M Grądalska-Lampart, AU 
Radziszewska (Subcarpathian Cancer Registry); A Gos (Varmian-Mazurian Cancer 
Registry); M Talerczyk, M Wyborska (West-Pomeranian Cancer Registry); JA Didkowska, 
U Wojciechowska (National Cancer Registry); M Bielska-Lasota (National Institute of 
Public Health, NIH); Portugal: G Forjaz de Lacerda, RA Rego (Registo Oncológico 
Regional dos Açores); J Bastos, MA Silva (Registo Oncológico Regional do Centro); L 
Antunes, J Laranja Pontes (Registo Oncológico Regional do Norte); A Mayer-da-Silva, A 
Miranda (Registo Oncólogico Regional do Sul); Romania: LM Blaga, D Coza (Cancer 
Institute I. Chiricuta); Russia: MY Valkov (Arkhangelsk Regional Cancer Registry); L 
Gusenkova, O Lazarevich (Population Cancer Registry of the Republic of Karelia); O 
Prudnikova, DM Vjushkov (Omsk Regional Cancer Registry); AG Egorova, AE Orlov 
(Samara Cancer Regional Registry); LA Kudyakov, LV Pikalova (Tomsk Regional Cancer 
Registry); Slovakia: J Adamcik, C Safaei Diba (National Cancer Registry of Slovakia); 
Slovenia: M Primic- Žakelj, V Zadnik (Cancer Registry of Republic of Slovenia); Spain: N 
Larrañaga, A Lopez de Munain (Basque Country Cancer Registry); AA Herrera, R 
Redondas (Registro Poblacional de Cáncer de la Comunidad Autónoma de Canarias); R 
Marcos-Gragera, ML Vilardell Gil (Epidemiology Unit and Girona Cancer Registry); E 
Molina, MJ Sánchez Perez (Granada Cancer Registry); P Franch Sureda, M Ramos 
Montserrat (Mallorca Cancer Registry); MD Chirlaque, C Navarro (Murcia Cancer 
Registry); EE Ardanaz, MM Guevara (Registro de Cáncer de Navarra); R Fernández-
Delgado, R Peris-Bonet (Registro Español de Tumores Infantiles); M Carulla, J Galceran 
(Tarragona Cancer Registry); C Alberich, M Vicente-Raneda (Comunitat Valenciana 
Childhood Cancer Registry); Sweden: S Khan, D Pettersson (Swedish Cancer Registry); P 
Dickman* (Karolinska Institutet, Stockholm); Switzerland: I Avelina, K Staehelin (Basel 
Cancer Registry); B Camey (Registre Fribourgeois des Tumeurs); C Bouchardy, R Schaffar 
(Geneva Cancer Registry); H Frick, C Herrmann (Cancer Registry Grisons and Glarus; 
Cancer Registry of St Gallen-Appenzell); JL Bulliard, M Maspoli-Conconi (Registre 
Neuchâtelois et Jurassien des Tumeurs); CE Kuehni, SM Redmond (Swiss Childhood 
Cancer Registry); A Bordoni, L Ortelli (Registro Tumori Canton Ticino); A Chiolero, I 
Konzelmann (Registre Valaisan des Tumeurs); KL Matthes, S Rohrmann (Cancer Registry 
Zürich and Zug); United Kingdom: J Broggio, J Rashbass (National Cancer Registration and 
Analysis Service England); D Fitzpatrick, A Gavin (Northern Ireland Cancer Registry); DI 
Clark, AJ Deas (Scottish Cancer Registry); DW Huws, C White (Welsh Cancer Intelligence 
& Surveillance Unit); C Allemani*, A Bonaventure, MP Coleman*, V Di Carlo, R 
Harewood, M Matz, L Montel, M Nikńić, B Rachet*, AD Turculeț (London School of 
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Hygiene & Tropical Medicine); R Stephens* (National Cancer Research Institute, London); 
C Stiller* (Public Health England)
Oceania—Australia: E Chalker, H Phung (Australian Capital Territory Cancer Registry); R 
Walton, H You (NSW Central Cancer Registry); S Guthridge, F Johnson (Northern Territory 
of Australia Cancer Registry); J Aitken, P Gordon (Queensland Cancer Registry); K 
D’Onise, K Priest (South Australian Cancer Registry); BC Stokes, A Venn (Tasmanian 
Cancer Registry); H Farrugia, V Thursfield (Victorian Cancer Registry); J Dowling (Western 
Australian Cancer Registry); D Currow* (Cancer Institute NSW); New Zealand: J Hendrix, 
C Lewis (New Zealand Cancer Registry)
* CONCORD Steering Committee
† Dr A Giacomin passed away on 23 March 2017.
Abbreviations
ALL acute lymphoblastic leukaemia
CDC US Centers for Disease Control and Prevention
DCO Death Certificate Only registration
IACR International Association of Cancer Registries
IARC International Agency for Research on Cancer
ICD-O International Classification of Diseases for Oncology
NAACCR North American Association of Central Cancer Registries
NPCR National Program of Cancer Registries
SDG Sustainable Development Goals
SEER Surveillance, Epidemiology and End Results programme
TNM Tumour Nodes Metastasis
UN United Nations
WHO World Health Organisation
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Panel: Research in context
Evidence before this study
In 2015, the second cycle of the CONCORD programme established global surveillance 
of cancer survival, as one of the key metrics of the effectiveness of health systems and to 
inform global policy on cancer control. This was done by analysis of individual records 
for 25.7 million patients diagnosed with one of 10 common cancers during 1995–2009 
and followed up to 31 December 2009. The data were provided by 279 population-based 
cancer registries in 67 countries.
CONCORD-2 revealed wide differences in cancer survival trends that were attributed to 
differences in access to early diagnosis and optimal treatment.
Added value of this study
CONCORD-3 covers almost one billion people world-wide. It includes 15 common 
cancers in adults and 3 common cancers in children. Data quality has improved. The 
results are timely: published within 3 years of the end of follow-up.
CONCORD-3 updates the world-wide surveillance of cancer survival to 2014. It includes 
data for over 37.5 million patients diagnosed with cancer during the 15-year period 
2000–2014. Data were provided by over 320 population-based cancer registries in 71 
countries and territories, including 26 countries of low or middle income; 47 countries 
provided data with 100% population coverage. The study now includes 18 cancers or 
groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast 
(women), cervix, ovary, prostate and melanoma of the skin in adults, together with brain 
tumours, leukaemias and lymphomas in both adults and children. These cancers represent 
75% of all cancers diagnosed world-wide every year, in both low- and high-income 
countries.
The use of a similar study design and the same statistical methods enables the evaluation 
of survival trends for 10 cancers over the 20-year period 1995–2014. For the first time, 
worldwide trends in survival are also available for cancers of the oesophagus, pancreas, 
brain, and lymphomas and leukaemias.
Implications of all the available evidence
The CONCORD programme enables comparative evaluation of the effectiveness of 
health systems in providing cancer care. It also contributes to the evidence base for global 
policy on cancer control.
CONCORD monitors progress towards the overarching goal of the 2013 World Cancer 
Declaration, to achieve “major reductions in premature deaths from cancer, and 
improvements in quality of life and cancer survival” by 2020. It provides evidence to 
support WHO policy following the Cancer Resolution passed by the World Health 
Assembly in 2017.
The International Atomic Energy Agency’s Programme for Action on Cancer Therapy 
(PACT) used CONCORD-2 results in 2015 to launch its world-wide campaign to 
highlight the global divide in cancer survival, and to raise awareness of persistent 
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inequalities in access to life-saving cancer services. The results were used in a Lancet 
Series on women’s cancers in 2016. The US Centers for Disease Control and Prevention 
has used the results in a 2017 supplement to the journal Cancer to inform cancer control 
policy designed to reduce racial differences in cancer survival.
CONCORD-3 can be expected to impact cancer control policy world-wide, especially in 
countries with low survival. The Organisation for Economic Co-operation and 
Development published CONCORD-3 results in 2017 as the official benchmark of cancer 
survival, among their indicators of the quality of health care in 48 countries world-wide. 
The survival estimates will also form part of The Lancet Oncology Commission on 
childhood cancer in 2018.
Future research will include examination of the impact of stage at diagnosis, compliance 
with treatment guidelines and the quality of healthcare on international differences in 
cancer survival.
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Text-figure 1. Recruitment of cancer registries
*Of the 400 operational registries invited; all other percentages refer to the number of 
registries at the top of each column. The number of countries excluded (black boxes) 
refers to those for which exclusions affected the only participating cancer registry or 
registries.
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Figure 1. Participating countries and regions: world (adults)
Registries in smaller countries are shown in boxes, at different scales.
See web-figures 1.1–1.29 for regional maps, and web-figure 1.30 for world map for 
childhood cancers.
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Figure 2. Global distribution of age-standardised five-year net survival (%) for adults (15–99 
years) diagnosed during 2010–2014 with colon cancer or breast cancer (women) and children (0–
14 years) diagnosed with acute lymphoblastic leukaemia: continent and country
Survival estimates for each country are ranked from highest to lowest within each continent. 
Where data were available for more than one registry in a given country, the survival 
estimates are derived by pooling the data for that country, but excluding data from registries 
for which the estimates are considered less reliable (see text).
See web-figures 2.1–2.18 for all 18 cancers included in CONCORD-3, and for each calendar 
period 2000–2004, 2005–2009, 2010–2014.
*Data with 100% coverage of the national population.
†National estimate not age-standardised.
§National estimate flagged as less reliable because the only available estimates are from a 
registry or registries in this category (see text).
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Figure 3. 20-year trends in age-standardised five-year net survival (%) for women (15–99 years) 
with breast cancer,* by calendar period of diagnosis (1995–1999, 2000–2004, 2005–2009 and 
2010–2014), continent (or continental region) and country
Estimates for women diagnosed during 1995–1999 are taken from the analyses for 
CONCORD-2.6 Where data were available for more than one registry in a given country, the 
survival estimates are derived by pooling the data for that country, excluding data from 
registries for which the survival estimates are considered less reliable (see text).
*See web-figures 3.1–3.18 for other cancers.
§Continent or continental region with one or more national estimates flagged as less reliable.
Standard ISO abbreviations for country names: Algeria - DZA; Argentina - ARG; Australia - 
AUS; Austria - AUT; Belgium - BEL; Brazil - BRA; Bulgaria - BGR; Canada - CAN; Chile 
- CHL; China - CHN; Colombia - COL; Costa Rica - CRI; Croatia - HRV; Cuba - CUB; 
Cyprus - CYP; Czech Republic - CZE; Denmark - DNK; Ecuador - ECU; Estonia - EST; 
Finland - FIN; France - FRA; Germany - DEU; Gibraltar - GIB; Guadeloupe - GLP; Hong 
Kong SAR - HKG; Iceland - ISL; India - IND; Ireland - IRL; Israel - ISR; Italy - ITA; Japan 
- JPN; Jordan - JOR; Kuwait - KWT; Latvia - LVA; Lithuania - LTU; Malaysia - MYS; 
Malta - MLT; Martinique - MTQ; Mauritius - MUS; Mongolia - MNG; Morocco - MAR; 
Netherlands - NLD; New Zealand - NZL; Nigeria - NGA; Norway - NOR; Peru - PER; 
Poland - POL; Portugal - PRT; Puerto Rico - PRI; Qatar - QAT; Republic of Korea - KOR; 
Romania - ROU; Russian Federation - RUS; Singapore - SGP; Slovakia - SVK; Slovenia - 
SVN; South Africa - ZAF; Spain - ESP; Sweden - SWE; Switzerland - CHE; Taiwan - 
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TWN; Thailand - THA; Turkey - TUR; United Kingdom of Great Britain and Northern 
Ireland - GBR; United States of America - USA
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Figure 4. Global range of breast cancer* survival among 296 cancer registry populations in 64 
countries: age-standardised five-year net survival (%) estimates for 6,420,288 women diagnosed 
during 2000–2014, by continent and calendar period of diagnosis
*See web-figure 4 for other cancers.
Each box-plot shows the range of survival estimates among all cancer registries for which 
suitable estimates could be obtained for patients diagnosed in each calendar period, in each 
continent. The number of registries included in each box-plot is shown in parentheses. 
Survival estimates considered less reliable are not included (see text). The vertical line inside 
each box represents the median survival estimate among all contributing registries (the 
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central value in the range, or 50th centile). The box covers the inter-quartile range (IQR) 
between the lower and upper quartiles (25th and 75th centiles). Where there are only a few 
widely scattered estimates, the median may be close to the lower or upper quartile. The 
extreme limits of the box-plot are 1.5*IQR below the lower quartile and 1.5*IQR above the 
upper quartile. Open circles indicate „outlier‟ values, outside this range.
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